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ABSTRACT 
Class I viral fusion glycoproteins facilitate fusion of the viral envelope with cell membranes and entry 
of the virus into the cell, through extensive short sequence-specific interactions. Regions mediating 
these interactions include the N-terminal hydrophobic fusion peptide, a pair of extended 4,3-
hydrophobic heptad repeats (HRs), a membrane-active membrane proximal external region (MPER), a 
hydrophobic transmembrane domain and the cytoplasmic tail region. In particular, the anti-parallel 
binding of the C-terminal HR to the central N-HR trimeric coiled-coil forms the 6-helix bundle fusion 
core. These interaction-mediating sequences are generally well preserved sequentially and 
structurally, allowing their peptidyl analogues to be developed as antiviral therapeutics and/or research 
reagents (e.g. HR-derived peptides). Novel targets for the development of antiviral drugs and viral 
detection reagents are required when facing drug-resistant viral strains, viral pathogens without 
effective and/or economical treatment, and newly emerging viral pathogens. This thesis focuses on the 
systematic identification of novel interaction-mediating sequences within Class I viral fusion 
glycoproteins, and the investigation of their involvements in viral replication as well as their potential 
applications in diagnosis and anti-viral interventions. 
In Paper I, peptide array scanning identified 34 spike (S) protein-derived peptides that bound to the S 
protein of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). These putative 
self-binding peptides contain five core octapeptide consensus sequences, among which the octapeptide 
GINITNFR was predicted to form β-zipper-mediated amyloid-like fibrils. The peptide C6 containing 
this sequence was subsequently shown to oligomerize and form amyloid-like fibrils. The potential of 
C6 to conduct β-zipper-mediated interactions was further applied to detect the S protein expression by 
immunofluorescence staining. The peptide array scanning in Paper I used the S protein ectodomain 
without the MPER and beyond. Using chemical crosslinking and immunofluorescence staining, in 
Paper II we could show that the S protein MPER could oligomerize and further heteromerize with the 
N-terminal internal fusion peptide (IFP). The MPER-derived peptides also inhibited the coronavirus 
entry in a dose-dependent manner, potentially through disrupting the MPER-mediated interactions. 
The ability of peptides derived from the MPER in inhibiting viral entry and infection was 
subsequently studied in Paper III, in the context of HIV-1. The antiviral activities of the HIV-1 Env 
MPER-derived peptides were abrogated upon Ala substitution of the Trp residues or deletion of the C-
terminal cholesterol-interacting motif. Unexpectedly, Ala substitutions of the Trp residues within 
HIV-1 Env significantly elevated the biosynthesis of another viral structural protein, the p55/Gag, 
which led to enhanced viral particle release. In Paper IV, besides the MPER we identified the signal 
sequence of HIV-1 Env as another region that could negatively regulate the expression of p55/Gag. 
The HIV-1 Env signal sequence, which mediates the co-translational translocalization of nascent Env 
polypeptide into the endoplasmic reticulum, inhibited the viral protein expression and production, 
probably at a post-ER-targeting stage. N-terminal truncations of the Env signal sequence significantly 
elevated the intracellular and intraviral levels of late viral proteins and the proviral genome 
transcription in a time- and dose-dependent fashion. Moreover, the truncations suppressed the HIV-1 
promotor (LTR)-driven expression of a reporter protein, suggesting that the Env signal sequence 
inhibited viral genome transcription through LTR-dependent interactions.  
This thesis focused on three novel interaction-mediating sequences within two Class I viral fusion 
glycoproteins, which could regulate the viral infectivity, at both viral entry and assembly, through 
protein-protein, protein-lipid, and/or protein-nucleic acids interactions. These sequences and the 
interactions that they are meditating could be further targeted by their peptidyl analogues for viral 
detection and/or inhibition.  
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1 INTRODUCTION 
1.1 VIRAL FUSION GLYCOPROTEINS 
Enveloped viruses deliver their contents into target cells through envelope-plasma membrane 
fusion, which is mediated by the viral fusion glycoproteins embedded in the viral envelopes. 
During this process, the fusion glycoproteins conduct extensive protein-protein and protein-
membrane interactions through a common step-wise scheme that involves the adoption of an 
essential ‘trimer-of-hairpin’ tertiary conformation [1-3]. Upon being triggered by receptor 
binding, and for some viruses by a change in pH, the metastable fusion-competent viral 
fusion glycoproteins undergo extensive structural rearrangements. They progressively 
transform from the prefusion conformation to a trimeric pre-hairpin intermediate that 
connects the opposing membranes through a hydrophobic fusion peptide/loop, and then to the 
final rod-like trimer-of-hairpin conformation where three C-terminal regions pack onto a 
central N-terminal trimeric core [4, 5]. These structural rearrangements and extensive 
interactions mediated by the viral fusion glycoprotein ultimately provide the free energy for 
the juxtaposition of the opposing membranes and the thereafter formation of the membrane 
stalk, the hemifusion intermediate, and eventually fusion pores. 
Despite the common mechanism in mediating membrane fusion, the viral fusion 
glycoproteins differ in their orientation on the viral surface, their major secondary structure, 
oligomeric state, location of the fusion peptide/loop, and most importantly, the structure of 
their trimer-of-hairpin inner cores [4]. Based on these differences, they are divided into three 
classes (Table 1). The Class I viral fusion glycoproteins encompass the envelope proteins of 
many medically important viruses including influenza virus [6], human immunodeficiency 
virus type 1 (HIV-1) [7] and severe acute respiratory syndrome-associated coronavirus 
(SARS-CoV) [8]. They are mostly synthesized as type I transmembrane precursor proteins 
and later oligomerize into trimeric peplomers, which are anchored perpendicularly from the 
plasma membrane, and after budding the viral envelope, through a single-pass C-terminal 
transmembrane domain. Based on the proteolytic cleavage site, the Class I viral fusion 
glycoproteins can be divided into two functional subunits, namely a surface subunit that 
interacts with the viral receptor and a fusion subunit that contains two Leu/Ile zipper heptad 
repeat (HR) regions. During viral entry, the HRs of the fusion protein trimers are responsible 
for forming a six-helix-bundle (6-HB) trimer-of-hairpin fusion core, where the three helical 
C-terminal HRs pack onto the grooves of a central coiled-coil formed by the three N-terminal 
HRs. The Class II viral fusion glycoproteins mostly contain surface proteins of the 
flaviviruses, alphaviruses and bunyaviruses [9, 10]. The Class II viral fusion glycoproteins 
are presented along the viral surfaces as dimers. During membrane fusion, their internal 
fusion loops induce the structural realignment into trimer-of-hairpins consisting of mostly β-
structure core. Finally, Class III viral fusion glycoproteins have combined features of the 
Class I and II fusion glycoproteins and are found on rhabdoviruses, herpesviruses and 
alphabaculoviruses [4].  
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The Class I viral fusion glycoproteins are the focus of this thesis, and their fusion 
mechanisms will be introduced in detail in the following sections with the prototype proteins, 
the SARS-CoV spike (S) protein and the HIV-1 envelope (Env) protein.  
 
Table 1. Viral fusion glycoprotein classification (Adapted from [4]). 
Features Class I Class II Class III 
Examples Influenza HA, HIV-1 Env TBEV E, SFV E1/E2 VSV G, HSV-1 gB 
Orientation with 
respect to viral 
membranes 
Perpendicular  
(spike-like) 
Parallel (close to the viral 
membrane) 
VSV G, perpendicular 
HSV-1 gB, unknown 
Major secondary 
structure (of the 
fusion subunit) 
α-helix β-sheet α-helix and β-sheet 
Prefusion 
oligomerization 
state 
Trimer Dimer VSV G, trimer 
FP location  
Near the N-terminus of 
the fusion subunit 
Internal Internal (bipartite) 
Fusion-active 
oligomerization 
state 
Trimer Trimer Trimer 
Fusion core 
structure 
Trimer-of-hairpin  
(6-HB) 
Trimer-of-hairpin  
(mainly β structure) 
Trimer-of-hairpin  
(central α-helical coiled 
coil accompanied with 
significant β-structure) 
Influenza HA, influencza hemagglutinin protein; TBEV E, tick-borne encephalitis virus envelope 
protein; SFV E1/E2, Semliki forest virus envelope protein E1/E2; VSV G, vesicular stomatitis virus G 
protein; HSV-1 gB, herpes simplex virus glycoprotein B.  
 
1.2 THE CLASS I FUSION GLYCOPROTEIN OF SARS-COV 
1.2.1 Severe acute respiratory syndrome (SARS) 
In November 2002, a large outbreak of an atypical and severe pneumonia named the severe 
acute respiratory syndrome, or SARS, was first reported in Guangdong, China. Person-to-
person transmission via infectious respiratory droplets and international travelling of infected 
individuals quickly led the illness to spread through 25 countries and five continents [11-13]. 
Starting as an influenza-like syndrome with fatigue, rigors and high fevers, SARS could 
progress to an atypical pneumonia in two-thirds of the infected individuals. The destruction 
of the alveolar and bronchial epithelial cells, and the increased production of pro-
inflammatory cytokines and chemokines may collectively result in respiratory failure, the 
most common cause of death among the infected. Besides the upper and lower respiratory 
tract symptoms, extra-pulmonary manifestations, such as liver and renal impairment, 
bradycardia, hypotension and lymphopenia, were also reported in SARS patients [14]. 
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Eventually, SARS resulted in 8,437 infected individuals and 813 deaths, between November 
2002 and July 2003, with a fatality rate of 9 to 12% and higher than 50% among elders over 
the age of 65 [15]. 
1.2.2 SARS-CoV 
1.2.2.1 Identification of SARS-CoV 
In April 2003, based on the results from serologic analysis, molecular analysis and 
microscopic studies, a new member from the Betacoronavirus genus, Coronavirinae 
subfamily and the Coronaviridae family was identified as the causative agent of SARS and 
was named the SARS-associated coronavirus (SARS-CoV) [16-19]. Coronaviruses are 
enveloped, positive-stranded RNA viruses that can infect a variety of vertebrates with 
respiratory and enteric diseases. They were primarily known for their adverse effects on 
economically important live-stocks, a picture that has been changed since the identification of 
SARS-CoV, and more recently another deadly human pathogen, the Middle East respiratory 
syndrome coronavirus (MERS-CoV) [20].  
1.2.2.2 SARS-CoV particle morphology and structure 
SARS-CoV shares similar viral morphology, genome structure and replication cycle with 
other coronaviruses. The enveloped SARS-CoV is coated with three structural proteins, the 
spike (S) glycoprotein, the membrane glycoprotein and the envelope protein [17]. The S 
proteins form the clubbed-shaped trimers on the viral surface, giving the SARS-CoV the 
characteristic crown-like (corona) appearance (Figure 1A-B) [17]. The membrane protein 
interacts with the fourth structural protein, the nucleocapsid protein, which coats the viral 
RNA genome (Figure 1C).  
 
 
Figure 1. SARS-CoV viral morphology and structure. (A) SARS-CoV particles containing club-
shaped peplomer structure on the viral surface (arrowhead) are aligned long the rough endoplasmic 
reticulum (ER) (arrow) as the virus bud into the cisternae [17]. (B) SARS-CoV shows an internal 
helical nucleocapsid-like structure and club-shaped surface projections. The bar in (A) and (B) 
represented 100 nm [17]. (C) Schematic representation of the SARS-CoV viral structure. 
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1.2.2.3 SARS-CoV genome  
The SARS-CoV genome has the characteristic features of a coronavirus genome [21] (Figure 
2). The ~27 kb, 5’-capped and 3’-polyadenylated RNA genome has a 5’ leader sequence, a 5’ 
untranslated region, two protein-coding regions and a second 3’ untranslated regions [22, 23]. 
The first protein-coding region contains two overlapping open reading frames that are 
translated into a single polyprotein by a -1 ribosomal frameshift. This polyprotein is further 
processed into the proteins required for transcription and replication. The second region 
encodes the four structural proteins and also contains the accessory genes. 
 
 
Figure 2. Schematic representation of the genome structure of SARS-CoV. Black boxes represent 
the 5’ and 3’ untranslated regions (UTR), followed by the two overlapping open reading frame (ORF) 
1a and 1b in white boxes. The grey boxes represent the coding regions for the structural proteins, the 
S, envelope (E), membrane (M) and nucleocapsid (N) proteins. The dark grey boxes represent the 
ORF encoding the accessory proteins. The positions of the leader sequence (L) and poly(A) tract are 
indicated.   
 
1.2.2.4 SARS-CoV replication cycle 
The replication cycle of SARS-CoV is initiated by the receptor recognition by the S protein 
and thereby the attachment of the virus onto the target cells [21, 24, 25] (Figure 3). The 
angiotensin converting enzyme 2 (ACE2) is the major viral receptor and is present in the 
tissues, which are susceptible to SARS-CoV infection. They include the heart, lung, kidney, 
and gastrointestinal tract [26, 27]. Although less effectively, SARS-CoV also can use 
CD209L/L-SIGN to enter the host cells [28]. The S protein-receptor interaction triggers the 
endocytosis of viral particles into early endosomes, where the low pH and proteolytic 
processing of the S protein by cathepsin L activates the Class I viral fusion protein machinery 
within the S protein, leading to the fusion of the envelope with the cell membrane and the 
release of the viral content into the cytoplasm [29-31]. The two 5’ overlapping open reading 
frames within the viral genomic RNA are then translated into a viral replicase polyprotein. 
Auto-cleavage of the viral replicase polyprotein leads to the assembly of the viral replication 
complex, which facilitates the synthesis of the nested subgenomic mRNA transcripts and the 
viral genome replication [32]. The subgenomic mRNA is then translated into viral structural 
proteins, i.e. the S protein, membrane protein, envelope protein and the nucleocapsid protein. 
The nucleocapsid protein further associates with the viral genomic RNA to form the 
nucleocapsid. The nucleocapsid then acquires the viral envelope by budding through the 
intracellular membranes between the endoplasmic reticulum (ER) and the Golgi apparatus, 
where the structural proteins translated in the ER are converged. Finally, the virions travel 
  5 
through the Golgi apparatus where they receive glycosylation modifications of the viral 
glycoproteins, and eventually reach the cell surface where they are released via exocytosis.  
 
 
Figure 3. Schematic representation of the coronavirus replication cycle.    
 
1.2.2.5 Anti-SARS treatment  
Ribavirin, a guanosine analogue previously used for the treatment of hepatitis C virus, 
another RNA virus, was prescribed alone or in combination with corticosteroid or the two 
HIV-1 protease inhibitors, lopinavir and ritonavir [13]. However, the efficacy of this 
treatment remains to be confirmed, due to the lack of controlled clinical trials and the 
inconclusive results generated from in vitro antiviral assays using different cell lines [14]. 
Traditional Chinese medicine was also prescribed in mainland China, but no systematic 
studies were conducted to evaluate the treatment outcome. Nevertheless, treatment with 
interferon-α and/or –β have shown some antiviral efficacy. Rational design of anti-SARS 
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drugs have also made some progress with the study on cyclosporin A, a ‘pan-coronavirus 
inhibitor’ that have exhibited antiviral effects against a large range of coronaviruses [33].  
1.2.3 SARS-CoV S protein 
1.2.3.1 SARS-CoV S protein biosynthesis and domains 
The SARS-CoV S protein is a 1255 amino acid (aa) long, Class I viral fusion glycoprotein 
synthesized following the secretory pathway. The N-terminal signal peptide (1-13 aa) of the S 
protein directs its co-translational translocation into the rough ER, where it is trimerized and 
extensively glycosylated on 23 putative N-glycosylation sites [23, 34, 35]. Upon the correct 
folding and trimerization in the ER, the S protein precursor is transported to Golgi apparatus, 
where it acquires the EndoH-resistant complex N-glycans [34]. Eventually, trimers of the S 
proteins are positioned on the viral membrane with the bulky N-terminal parts projecting out 
of the virion, which form the characteristic club-shaped trimeric peplomers as observed by 
electron microscopy (Figure 4A).   
Unlike the spike proteins of most coronaviruses, SARS-CoV S protein is not proteolytically 
processed in the Golgi [34]. Instead, it is cleaved and activated during the viral entry, by the 
endosomal enzymes cathepsin L after its Thr678 or by trypsin at Arg792 [36, 37]. Based on 
the cathespsin L cleavage site, the S protein is arbitrarily divided into the surface S1 subunit 
and the transmembrane S2 subunit (Figure 4B). The S1 subunit is composed of a signal 
peptide (1-13 aa) at its N terminus, followed by a receptor binding domain (RBD) (318-510 
aa) containing the receptor binding motif (RBM) (424-494 aa) [24, 38-40]. The S2 subunit 
contains two N-terminal hydrophobic domains, a fusion peptide (FP) domain (770-788 aa), 
an internal fusion peptide (IFP) domain (873-888 aa); two heptad repeat (HR) regions 
containing Leu/Ile zipper sequences, the HR1 (892-1013 aa) and HR2 (1145-1190 aa); a 
hydrophobic membrane proximal external region (MPER), a transmembrane (TM) domain 
and a C-terminal cytoplasmic tail [41-45].  
 
 
Figure 4. SARS-CoV S protein architecture and domains. (A) Atomic resolution structure 
reconstructed from cryo-electron microscope images [46] (left), and the schematic representation 
(right) of the prefusion S protein trimers (B) Schematic representation of the S protein domains. 
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1.2.3.2 S protein-mediated viral entry 
The S protein mediates the envelope-cell membrane fusion and SARS-CoV entry through a 
Class I viral fusion mechanism [8, 47]. To execute fusion between the two closely positioned 
membranes, lipid bilayers need to be mixed and remodeled to form a hemifusion stalk, 
hemifusion diaphragm and eventually a fusion pore [48] (Figure 5). However, the membrane 
lipid bilayer is stabilized by a powerful hydrophobic effect, which acts against any structural 
changes. Any membrane remodeling would require energy investment, which comes from 
thermal fluctuations of the membrane itself and/or specialized protein involvement. 
 
 
Figure 5. Schematic representation of the membrane fusion process. 
 
The Class I viral fusion glycoproteins facilitate the membrane fusion through extensive 
protein-protein and protein-membrane interactions, which involve the formation of a 6-HB 
fusion core (Figure 6). Firstly, the RBD within the S1 subunit recognizes and interacts with 
the primary viral receptor ACE2 and induces the endocytosis of the virions [38]. Within the 
endosomes, the S protein will be activated by the low pH and/or the proteolytic cleavage by 
the endosomal enzymes such as cathepsin L [49]. This leads to structural rearrangements 
within the S protein and the exposure of the FP region situated at the S2 subunit N-terminus. 
Subsequently, it is believed that the exposed FP inserts into the target cell membrane, leading 
the S protein to adopt a pre-hairpin intermediate where the two HRs are extended and 
transiently exposed. It has been suggested that the HR2 adopts a trimeric helical structure at 
this stage [50]. The pre-hairpin intermediate would slowly but eventually resolve into a more 
energetically favorable state by folding the C-terminal HR2 anti-parallel onto the N-terminal 
HR1. This leads to the formation of the 6-HB fusion core, where each of the HR2 helix binds 
to each of the three grooves of the trimeric HR1 coiled-coil. It is believed that the formation 
of the 6-HB provides the free energy to juxtapose the opposing membranes that are kept 
separated by the hydrophobic effect, which generates a locally anhydrous environment 
facilitating the subsequent lipid mixing and membrane fusion. By the end of the lipid mixing, 
according to the Class I membrane fusion model, the N- and the C-termini of the S proteins 
are located on the same side of the fused membrane in the post-fusion conformation. 
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Figure 6. SARS-CoV S protein mediates the viral entry and membrane fusion via the Class I 
viral fusion mechanism. The entry scheme is presented with the structures of the ACE2-RBD 
complex [38], the prefusion HR2 (1141-1193 aa) [50] and the trimer-of-hairpin fusion core (HR1: 
898-1005 aa, HR2: 1145-184 aa) [47]. Within the ACE2-RBD structure, green, ACE2; red, RBM; 
blue, the rest of the RBD. Within the trimeric HR2 structure, red, blue and green each represents a 
HR2 helix.   
  
1.3 THE CLASS I FUSION GLYCOPROTEIN OF HIV-1  
Although HIV-1 mainly infects CD4+ T lymphocytes, it can also infect macrophages, 
monocytes and dendritic cells. As the HIV-1 infection progresses, it depletes and exhausts the 
CD4+ T lymphocytes, thereby weakening the immune system, allowing opportunistic 
infections to occur, eventually resulting in a life-threatening immunodeficiency disease 
named the acquired immunodeficiency syndrome or AIDS. 
1.3.1 Acquired immunodeficiency syndrome (AIDS) 
1.3.1.1 The AIDS epidemic  
Since 1982, when AIDS was first officially recognized and named by the U.S. Centers for 
Disease Control and Prevention, there has been approximately 36 million AIDS-related 
deaths, and presently 35.3 million people are living with HIV-1 infection [51]. In 2012, the 
UNAIDS reported 2.3 million new HIV infections and 1.6 million AIDS deaths globally [51]. 
The epidemic has substantial effects in sub-Saharan Africa, where 24.7 million people were 
estimated to live with HIV in 2013. More recently, HIV-1 infection has become a major 
concern also in East Asia, Central Asia and Eastern Europe.  
1.3.1.2 HIV transmission and pathogenesis 
HIV-1 was isolated and identified as the etiological agent of AIDS between 1983 and 1984 
[52-56]. In 1986, HIV-2, a closely related virus to HIV-1, was identified as the second AIDS-
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causing agent [57]. So far, most of the HIV infections worldwide are with HIV-1, while the 
HIV-2 infections are confined mainly to West Africa.  
HIV can infect the host through free viral particles and/or infected cells in the blood, semen, 
vaginal fluids and breast milk. It is mostly transmitted through sexual intercourse, 
intravenous drug abuse and by mother-to-child transmission. Although the rate of progression 
varies greatly among infected individuals, an HIV infection generally progresses through 
three stages, the primary/acute infection, the asymptomatic infection, and finally AIDS [58]. 
The acute HIV infection stage generally lasts 2 to 10 weeks after the initial infection. During 
this period, HIV replicates rapidly and acutely depletes the CD4+ T lymphocytes in the gut-
associated lymphoid tissues, and the infected individuals usually experience no symptom or a 
brief flu-like illness [59]. Subsequently, the host immune system responds and generates anti-
HIV antibodies and cytotoxic lymphocytes, which subsides the viral load to a lower stable 
level and leads the infection to the second asymptomatic stage. At this clinically latent stage, 
the infected individual experiences minimal symptoms and could remain apparently healthy 
for an average of 10 years [60]. However, the CD4+ T cells counts continuously drop and 
thus the immune system gradually becomes weaker. When CD4+ T lymphocytes counts drop 
to fewer than 200 cells /µl, symptomatic opportunistic infections appear and the HIV-1 
infections enter the last stage AIDS.   
1.3.2 HIV-1 
1.3.2.1 HIV-1 classification  
HIV-1 is classified in the Lentiviruses genus of the Orthoretrovirinae subfamily of the 
Retroviridae, which is characterized by a long latency period and a slow onset of symptoms. 
Among the four HIV-1 groups, M, N, O and P, Group M is the major circulating group 
responsible for the global epidemic. It is divided into more than 8 subtypes that could further 
generate between-subgroup recombinants [61].  
1.3.2.2 HIV-1 viral genome, proteins and morphology 
Each HIV-1 viral particle contains two copies of a 9.2 kb single-stranded and positive-sensed 
RNA genome (Figure 7), which is reversely transcribed and integrated into the host genome 
upon viral infection [62]. The resulting provirus within the host genome is flanked by two 
long terminal repeats (LTRs) each composed of an U3 (unique, 3’ end), a R (repeated) and an 
U5 (unique, 5’ end) region [63]. The 5’ LTR directs the transcription and the generation of 
the viral RNA transcripts, while the 3’ LTR serves as the transcription termination signal 
[64]. Transcription of the viral genome generates the full-length viral RNA transcripts that 
either remain unspliced or spliced to different extent through an alternative splicing 
mechanism (Figure 7).  
The viral mRNA transcripts eventually give rise to fifteen viral proteins. The ~9kb full-length 
mRNA transcript is used to express p55/Gag (group-specific antigen) and, upon a -1 
ribosomal shift, the p160/Gag-Pol (Gag-polymerase) polyproteins. The ~4kb incompletely 
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spliced mRNA transcripts, depending on the splicing sites, are used to express the Env 
(envelope protein), Vif (virion infectivity factor), Vpr (virion protein R), Vpu (virion protein 
U) and the one-exon Tat (trans-activator of transcription) proteins. The ~1.8kb completely 
spliced mRNA transcripts are used to express the Rev (regulator of virion protein 
expression), Nef (negative regulatory factor) and the two-exon Tat.   
 
 
Figure 7. HIV-1 RNA genome structure. Transcription of the HIV-1 proviral genome within the 
host genome generates the full-length viral mRNA transcripts, which either remain unspliced or 
spliced to different extent through alternative splicing. ORFs encoding different viral proteins are 
colored according to the extent of splicing. The packaging signal (Ψ) that regulates the packaging of 
the RNA genome into the viral capsid is depicted. 
 
The fifteen HIV-1 proteins are grouped into the structural, the accessory and the regulatory 
proteins. The viral structural proteins are expressed as the precursor Env, p55/Gag, and 
p160/Gag-Pol proteins. They are the essential parts of the HIV-1 viral particles. When the 
viral particles are first assembled, arrays of the p55/Gag polyproteins are connected with the 
viral envelope, which gives the immature viral particle a characteristic doughnut shape when 
observed by electron microscopy (Figure 8A) [65]. During or soon after viral budding, the 
viral protease within p160/Gag-pol auto-cleaves itself and thereafter processes the p55/Gag 
into the matrix, capsid, nucleocapsid and p6, and cleaves the p160/Gag-pol additionally into 
the reverse transcriptase and integrase [66-68]. This leads to the rearrangement of the 
p55/Gag-derived structural proteins and the maturation of the viral particles, characterized by 
a cone-like structure within the viral particle (Figure 8A, B) [65, 69, 70]. Within the mature 
HIV-1 particle, two copies of the viral RNA genome are each encapsulated by nucleocapsid 
proteins and are further dimerized. The resulting nucleocapsid, together with the viral 
integrase and reverse transcriptase, are subsequently surrounded by a cone-shaped structure 
composed of the capsid proteins and a spherical shell composed of the matrix protein. The 
viral capsid is eventually enveloped by the host-derived viral lipid bilayers, which is studded 
with the trimeric Env proteins composed of non-covalent heterodimers of the surface gp120 
protein and the transmembrane gp41 protein.  
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Figure 8. HIV-1 viral morphology. (A) HIV-1 morphological change during viral maturation [65]. 
Top row, single tomographic slices through the particle volume showing the complete views of the 
capsid structures; bottom row, full 3D segmentation of the entire particle volume. Purple, membrane; 
green, immature capsid; red, mature capsid (B) Schematic representation of the mature HIV-1 virion. 
 
The regulatory proteins include Tat and Rev. Tat is essential for activating the transcription of 
the HIV-1 provirus. Rev regulates the post-transcriptional alternative splicing of the viral 
transcripts.  
The accessory proteins, Vpu, Vif, Vpr and Nef, regulate the viral infectivity through 
interacting with various cellular proteins, which are further elaborated in the next section 
‘HIV-1 replication cycle’. Vpr, Nef and variable amounts of Vpu and Vif have been detected 
in the HIV-1 virions [71-74]. 
1.3.2.3 HIV-1 replication cycle 
The HIV-1 replication cycle is initiated by the recognition of the viral receptors, CD4, by the 
surface gp120 unit of the Env proteins (Figure 9) [75, 76]. This induces structural 
rearrangement within gp120, allowing its interaction with the co-receptor, CCR5 or CXCR4 
[77-82]. This in turn introduces further conformational changes, which exposes the 
transmembrane gp41 unit of Env and activates the Class I fusion mechanism within gp41 [83, 
84]. It ultimately leads to the fusion between the viral and the cellular membranes, and the 
release of the viral capsid into the host cells. Within the released nucleocapsid, the viral RNA 
is reversely transcribed by the viral reverse transcriptase [85]. The viral reverse transcriptase 
lacks proofreading ability and its error-prone reverse transcription introduces mutations 
within the HIV-1 provirus and results in a high genetic variability of HIV-1 [86]. After the 
reverse transcription, a pre-integration complex is formed by the double-stranded viral DNA, 
the matrix protein, the integrase and some host factors and is transported into the host nucleus 
[87, 88]. Within the nucleus, the viral DNA is integrated into the host genome by the viral 
integrase.  
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Figure 9. HIV-1 replication cycle. (A) Env binding to the receptor CD4 and the co-receptor 
CCR5/CXCR4 initiates the HIV-1 replication cycle. (B) Receptor binding triggers series of structural 
rearrangement within Env, which lead to the fusion between the viral and cell membranes, and to the 
release of viral capsid into the host cells. Within the released viral capsid, the viral RNA genome is 
reversely transcribed into double-stranded DNA. (C) The synthesized viral DNA, together with the 
matrix, integrase and host factors, is transported into the host nucleus, where the viral DNA is 
integrated into the host genome. (D) Provirus genome is transcribed at a baseline level. (E) The 
multiply spliced mRNA transcripts are then exported to the cytoplasm for the translation of viral 
protein Tat, Rev and Nef. Tat and Rev are then transported back to the nucleus, where Tat boosts the 
provirus transcription and Rev rescues the mRNA transcripts from multiple splicing. (F) The partially 
or un-spliced mRNA is used for the synthesis of Env, (G) p55/Gag and p160/Gag-pol and for the (H) 
viral assembly. (I) The synthesized structural proteins Env, p55/Gag and p160/Gag-pol converge onto 
the viral assembly site. (J) — (K) During, or soon after viral budding, the protease autocleaves from 
the p160/Gag-pol, leading to the viral maturation.  
 
After integration, baseline levels of viral proviral mRNA are transcribed, multiply spliced and 
used to express the early viral proteins Tat, Rev and Nef. Tat and Rev are then transported 
back to the nucleus. Tat binds to the transactivation response region located within the 5’ 
LTR region of the nascent viral mRNA, which greatly enhances the processivity of the RNA 
polymerase II and hence boosts the transcription of the HIV-1 provirus [89-92]. Meanwhile, 
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the Rev protein targets the Rev response element (RRE) within the env gene, binds to the 
partially or un-spliced RNA transcripts, and rescues them from multiple splicing by 
facilitating their export out from the nucleus [93].   
The unspliced RNA transcript is packaged as the genomic material into the viral particles and 
is also used to express the p55/Gag and p160/Gag-pol proteins by the cytosolic ribosomes. 
The p55/Gag and p160/Gag-Pol are then transported to the viral assembly site on the cell 
surface lipid rafts [94, 95]. The other structural protein Env precursor gp160 is translated 
from a partially spliced RNA species by the rough ER-associated ribosomes. In the ER, Env 
undergoes glycosylation, structural isomerization, and trimerization prior to its export to the 
Golgi apparatus [96, 97]. In the Golgi, the Env gp160 is further proteolytically processed into 
the non-covalent heterodimer gp41/gp120 [98], which is then transported to the viral 
assembly site to join the p55/Gag and p160/Gag-pol proteins [99, 100]. Both direct and/or 
indirect interactions between gp41 and p55/Gag components have been suggested to initiate 
the incorporation of Env into the budding viral particles [101]. During, or shortly after, viral 
budding, the viral protease auto-cleaves from the p160/Gag-pol and leads to the structural 
rearrangement within and the maturation of the HIV-1 virions. 
Although not always required for viral infection in vitro, the viral accessory proteins, Vpu, 
Vif, Vpr and Nef, enable the virus to overcome the host restrictions and evade the host 
antiviral responses in vivo through interacting with various cellular proteins [102, 103]. Vpu 
interacts with the ER-residing CD4 molecules and targets it for ubiquitine-mediated 
proteosomal degradation [104-106]. This prevents the nascent Env molecules from binding to 
the ER-residing CD4 prematurely, which could inhibit the Env from being incorporated into 
the budding virions. Vpu has also been found to down-regulate and counteract the host 
restriction factor tetherin. Tetherin is a transmembrane protein that could be simultaneously 
anchored onto both the cellular and the viral membranes and thereby tether the budded 
virions onto the cellular membrane and prevent their release for further infection [107]. Vif 
counteracts another host restriction factor, the apolipoprotein B mRNA editing complex 3G 
protein or simply APOBEC3G, by targeting it to ubiquitine-mediated degradation and 
preventing its incorporation into the virions [108-110]. APOBEC3G exerts several anti-viral 
activities [102, 111]. It attacks single-stranded DNA by converting cytidine to uridine, which 
results in guanosine-to-adenosine hypermutations within proviruses and the subsequent 
production of non-infectious viral particles. Furthermore, APOBEC3G could inhibit the 
processivity of the reverse transcriptase and upregulate the natural killer cell-mediated lysis 
of the infected cells. The third accessory protein Nef enables the viral infection to evade 
cytotoxic T lymphocytes and promotes viral budding, through its interactions with the host 
clathrin adaptor proteins. Nef stabilizes the interaction between the clathrin adaptor proteins 
with the histocompatibility complex class I (MHC-1), which leads to the mislocalization and 
subsequent degradation of MHC-1 along the endolysosomal pathway [112-114]. Nef can also 
concurrently interact with the clathrin adaptor protein and the cytoplasmic tail of CD4, which 
facilitate the down-regulation of CD4 from the cell surface [115, 116]. This inhibits the 
retention of virions on the cell surface through Env-CD4 interaction, and therefore promotes 
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virus release. Finally, Vpr promotes viral infectivity through multiple mechanisms, including 
enhancing HIV-1 replication in lymphocyte- and monocyte-derived cell lines, inducing host 
cell cycle arrest and promoting the nuclear translocation of the HIV-1 pre-integration 
complex [103].  
1.3.2.4 Anti-retroviral therapy 
In 2012, UNAIDS reported a 33% decrease in the annual new HIV-1 infection cases as 
compared to that in 2001. Also, in 2012, the number of AIDS deaths declined to 1.6 million, 
from 2.3 million in 2005. This is largely owing to the development and availability of 
antiretroviral medications. So far, there are 24 Food and Drug Administration (FDA)-
approved antiretroviral drugs, which are categorized by their targets into protease inhibitors, 
nucleoside/nucleotide analogue reverse transcriptase inhibitors, non-nucleotide analogue 
reverse transcriptase inhibitors, entry inhibitors and the integrase inhibitors [117]. The HIV-1 
reverse transcriptase is error-prone and could introduce one to ten mutations per copy per 
replication cycles. This results in an enormous genetic diversity and the emergence of drug-
resistant HIV-1 quasispecies [118]. In fact, the HIV-1 quasispecies with reduced 
susceptibility to any one or two drugs likely exist within patients even before therapy [119]. 
In light of this, it is recommended to include three different antiretroviral drugs in the 
treatment regimen named HAART (highly active antiretroviral therapy) or lately just ART. 
HAART effectively reduces the likelihood of selecting virus clones that are resistant to all 
three antiretroviral drugs. However, HAART cannot eliminate HIV infection. To suppress the 
viral replication, the patients are required to maintain a lifetime drug adherence. Besides non-
adherence, virological failure could be attributed to poor drug tolerability and drug 
interactions that could inhibit the antiretroviral efficacy, which collectively lead to the 
evolution of drug resistance and therefore there is a continuous need for new anti-HIV 
treatments [117].  
1.3.3 HIV-1 envelope protein 
1.3.3.1 HIV-1 Env protein biosynthesis and domains 
HIV-1 Env protein is a ~860 aa type I transmembrane protein which is translated from a 
singly spliced bicistronic vpu/env mRNA [120, 121]. Its synthesis and maturation follow the 
host cellular secretory pathway. Nascent Env is translated with an N-terminal signal sequence 
(ss) region (1-30 aa), which directs the co-translational translocation of nascent Env into the 
rough ER [122]. Different from the common ss that is cleaved off during or upon the protein 
translocation and sent for degradation, the Env ss stays within the nascent Env polyprotein for 
a prolonged period. This unusually delayed cleavage, which is catalyzed by an ER resident 
signal peptidase (SPase), has been found to strongly contribute to the slow folding process of 
the nascent Env [122, 123]. Specifically, the presence of the Env ss correlates with the 
interactions between nascent Env and various chaperone proteins in the ER, such as Bip and 
calnexin [122-125]. Upon the correct disulfide bond isomerization and folding of Env, the ss 
is liberated, while the Env/gp160 assembles predominantly into trimers and are transported to 
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the Golgi apparatus [97, 126-128]. In the Golgi, the Env/gp160 receives further glycosylation 
modification and proteolytic processing by furin or furin-like proteases. Furin processes the 
Env/gp160 at the highly conserved poly-basic cleavage site K/R-X-K/R-R, resulting in the 
surface unit gp120 and the transmembrane unit gp41 (Figure 10A) [98, 129]. This process is 
essential for the viral infectivity. The two units, gp120 and gp41, remain non-covalently 
associated and are then transported to the cell surface for viral budding [130, 131].  
The error-prone HIV-1 reverse transcriptase introduces high level of mutations during the 
viral replication cycles. Based on the sequential variation between the Env of different HIV-1 
strains, the surface unit gp120 is divided into five variable (V) regions interspersed by 
multiple conserved (C) regions (Figure 10B) [132, 133]. The Env transmembrane unit gp41 
has a typical organization of a Class I viral fusion glycoprotein, composed of an N-terminal 
fusion peptide, two HRs, the MPER, the TM domain and a long cytoplasmic tail (Figure 
10B).  
 
  
Figure 10. HIV-1 Env protein architecture and domains. (A) Atomic resolution structure 
reconstructed from electron microscope images [134] (left), and the schematic representation (right) of 
the prefusion Env protein trimers. (B) Schematic representation of the Env protein domains. Cleavage 
sites by the signal peptidase (SPase) and by furin are indicated by the arrowheads. The numbering of 
the domains is based on the HIV-1 NL4-3 strain.   
 
1.3.3.2 Env-mediated viral entry 
The Env protein mediates the HIV-1 entry through a Class I viral fusion mechanism, similar 
to that of the S protein-mediated SARS-CoV entry (Figure 6). Structurally, the surface unit 
gp120 is composed of an inner domain, a β-sheet ‘bridging sheet’ domain, and an outer 
domain (Figure 11A) [135]. Elements of all three domains constitute a deep pocket of 
roughly 10 Å that interacts with the viral receptor CD4 molecule [135]. Recognition of the 
viral receptor introduces extensive structural rearrangement within the gp120, priming its 
interaction with the co-receptors, the chemokine receptors CCR5 or CXCR4. The V3 loop 
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within gp120 is essential for the chemokine co-receptor interaction and determines the viral 
tropism [136, 137]. It is believed that the chemokine receptor recognition introduces further 
conformational changes within Env, leading the exposure of the N-terminal FP within gp41 
[82, 138-140]. The exposed FP then inserts into the target membrane, and induces the 
formation of the pre-hairpin intermediate state and subsequently the 6-HB fusion core 
between the HR1 and HR2 regions (Figure 11B) [7, 97, 141].  
 
 
Figure 11. HIV-1 Env structure during viral entry. (A) 
Structure of the gp120, in complex with CD4 and the antibody 
fragment of 17b [135]. (B) Structure of the putative HIV-1 
fusion core [141].  
 
 
 
 
 
1.4 THE MPER OF CLASS I VIRAL FUSION GLYCOPROTEINS 
Class I viral fusion glycoproteins mediate the membrane fusion through forming the 6-HB 
fusion cores, which releases the free energy to approximate the opposing membranes 
separated by hydrophobic effects. The formation of 6-HB also predisposes MPER, the region 
following the HR2, to an increasingly lipidic environment. MPER is a conserved 
hydrophobic pre-TM domain among the Class I viral fusion glycoproteins [43, 142-146]. Its 
unusual enrichment in aromatic residues, particularly tryptophan (Trp), indicates its 
involvement in lipid mixing and membrane remodeling [147-150].  
Furthermore, the MPER of several Class I viral fusion glycoproteins, including the SARS-
CoV S protein and HIV-1 gp41, contains a sequence similar or identical to the cholesterol 
recognition amino acid consensus (CRAC) motif, -L/V-(X)(1-5)-Y-(X)(1-5)-R/K, where 
(X)(1-5) represents 1-5 of any amino acid [151, 152]. Cholesterol, together with 
sphingolipids are the key components of lipid rafts, functional membrane microdomains that 
are enriched with membrane-associated proteins [153]. While the viral entry through lipid 
rafts is facilitated by local concentration of viral receptors, cholesterol increases the 
membrane rigidity that might impede the membrane fusion process [154-157]. The MPER 
could counteract this effect and facilitates membrane fusion through CRAC-cholesterol 
interactions.  
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1.4.1 SARS-CoV S protein MPER 
The S protein MPER (1191-1201 aa) is well conserved among coronaviruses (Table 2). It 
contains three conserved Trp residues, and its N-terminus together with the upstream HR2 
sequence constitutes a CRAC motif LGKYEQYIK (Table 2). Truncations of the S protein 
MPER and/or alanine (Ala) substitutions of its Trp residues abrogate viral infectivity [158-
160]. Biophysical studies using synthetic SARS-CoV S protein MPER-derived peptides 
further suggest that the MPER facilitates the membrane fusion and the coronavirus entry 
through membrane partitioning and perturbation [142]. The formation of the 6-HB fusion 
core in the S protein would also predispose the regions flanking the two HRs, the N-terminal 
FPs and the C-terminal MPER, into proximity. The potential interactions between these 
regions have been suggested previously. However, discrepancies exist in the results generated 
by using artificial lipid monolayers under different setting [161].    
 
Table 2. MPER is highly conserved among coronaviruses fusion glycoproteins. 
Genus Virus MPER sequence 
Betacoronavirus 
BCoV YINLKDIGTYEYYVKWPWYVWL---LIGFAGVAMLVLLF
a 
HCoV-OC43 YINLKDIGTYEYYVKWPWYVWL---LICLAGVAMLVLLF 
HEV YINLKDIGTYEYYVKWPWYVWL---LIGLAGVAMLVLLF 
MHV YINLKDVGTYEMYVKWPWYVWL---LIGLAGVAVCVLLF 
SARS-CoV LIDLQELGKYEQYIKWPWYVWLGF-IAGLIAIVMVTILL 
Alphacoronavirus 
TGEV LVNLEWLNRIETYVKWPWYVWL---LIGLVVIFCIPLLL 
CCoV LVNLEWLNRIETYVKWPWYVWL---LIGLVVIFCIPLLL 
FCoV LVDLEWLNRIETYVKWPWYVWL---LIGLVVIFCIPLLL 
PEDV LVDLEWLNRVETYIKWPWYVWL---IIVIVLIFVVSLLV 
HCoV-229E LVDLKWLNRVETYIKWPWWVWL---CISVVLIFVVSMLL 
Gammacoronavirus IBV LIDLEKLSILKTYIKWPWYVWLAIAFATIIFILILGWVF 
Deltacoronavirus PorCoV HKU15 LVDLEWLNRVETYLKWPWYIWLAIALALIAFVTILITIF 
aMPER sequences are shaded and the conserved Trp residues in bold.  
BCoV, bovine coronavirus; HCoV-OC43, human coronavirus OC43; HEV, porcine hemagglutinating 
encephalomyelitis virus; MHV, murine hepatitis virus; TGEV, transmissible gastroenteritis virus; 
CCoV, canine coronavirus; FCoV, feline coronavirus; PEDV, porcine epidemic diarrhea virus; 
HCoV-229E, human coronavirus 229E; IBV, avian infectious bronchitis virus; PorCoV HKU15, 
Porcine coronavirus HKU15. 
 
1.4.2 HIV-1 Env MPER  
HIV-1 Env MPER is essential for viral entry and infectivity, by mediating the formation and 
expansion of the lytic pores for viral content delivery [162, 163]. The HIV-1 Env MPER is 
also a hot-spot for immunological studies. Three epitopes of the broadly neutralizing 
antibodies, 2F5, 4E10 and Z13e, have been identified in this region [15, 164]. This also 
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makes the HIV-1 Env MPER a relatively well characterized region, as compared to the 
MPER of other Class I viral fusion glycoproteins.   
The Env MPER contains two highly conserved membrane-active sequence elements, the five 
Trp residues and a C-terminal CRAC motif LWYIK, which both contribute to the activity of 
MPER in membrane fusion (Table 3) [133, 164]. Trp residues are essential for the MPER-
derived peptides to partition into, fuse, and/or cause leakage in artificial lipidic vesicles [145, 
165-167]. Both the viral envelope and the viral entry site, i.e. plasma membrane lipid rafts, 
are enriched in cholesterol. High local concentration of cholesterol induces the formation of 
ordered membrane domains, which usually hinders water-membrane partitioning and 
subsequent assembly of lytic pores. The MPER CRAC motif LWYIK counteracts this effect 
by interacting specifically with cholesterol, sequestering it into ordered domains, and 
enabling the MPER-derived peptides to partition deeper into cholesterol-enriched membranes 
(~50% cholesterol). In fact, the membrane destabilization effect of the MPER-derived 
peptides could be enhanced by introducing cholesterol into lipid membranes, in a dose-
dependent manner [167, 168].  
 
Table 3. HIV-1 Env MPER is highly conserved [133]. 
Group : subtype MPER sequence 
M:A AQVQQEQNEKKLLELKEWASIWNWLDITKWLWYIKIAIIIVGAa,b 
M:B SQIQQEKNEKELLELDKWASLWNWFSITQWLWYIKIFIMIVGG 
M:C SQNQQEQNEKDLLALDKWQNLWSWFDITNWLWYIKIFIMIVGG 
M:D SQNQQEKNEKDLLELKQWANLWNWFTISNWLWYIKIFIMIVGG 
O SQIQQEKNEQDLLALDKWANLWNWFDITNWLWYIKIFIMIVGG 
aMPER sequences are shaded and the conserved Trp residues in bold. bThe CRAC motif is underlined. 
 
Besides its membrane reactivity, the MPER could also facilitate the membrane fusion 
through self-oligomerization and heteromerization with the N-terminal FP domain, both in a 
Trp-dependent manner [166, 168-171]. Particularly, the post-6-HB formation of the MPER-
FP complex is believed to serve as a continuum structure to the 6-HB, which could provide 
extra free energy for juxtaposing the opposing membranes, enhance the local hydrophobicity, 
and enable the lipid flow.  
With the increase of local environment lipidity, Env MPER is also believed to undergo 
structural transition. Under aqueous condition, higher temperature and/or higher pH (~6), 
MPER is believed to contain high percentage of extended β- or turn-motifs [172, 173]. When 
it is associated with lipidic vesicles, the MPER-containing constructs adopt a solvent-exposed 
N-terminal α-helix and a membrane-embedded C-terminal α-helix, separated by a center 
hinge region [173, 174].  
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1.5 APPLICATIONS OF THE INTERACTION-MEDIATING SEQUENCES WITHIN 
THE CLASS I VIRAL FUSION GLYCOPROTEINS 
Viral fusion glycoproteins are important targets for therapeutic interventions. Entry and 
fusion inhibitors inhibit the first steps of viral infection and replication and, therefore, are 
considered more effective in viral inhibition, as compared to antivirals targeting the 
subsequent steps of viral replication. However, viral fusion glycoproteins are usually heavily 
glycosylated and could be constantly evolving, camouflaging their functionally important 
regions from immune surveillance and rendering antiviral targeting difficult. The interaction-
mediating regions or short sequences within the Class I viral fusion glycoprotein, for example 
the RBD, HRs, and MPER, conduct extensive infection-required protein-protein and/or 
protein-ligand interactions. To maintain the interactions and viral infectivity, these sequences 
are usually well conserved and potentially exposed, as evidenced by the identification of 
multiple broadly neutralizing antibodies that target regions including the CD4-binding site, 
HR1, and MPER [164, 175-181]. These characteristics render these interaction-mediating 
sequences attractive targets for the development of therapeutics, vaccines and research 
reagents [38, 47, 182-187]. The current viral entry/fusion inhibitors mainly focus on two 
interactions, the RBD-receptor interaction leading to the viral attachment, and the HR1-HR2 
interaction leading to the formation of the 6-HB fusion core.  
1.5.1.1 Receptor/Co-receptor recognition  
Many molecules have been shown to be potent in inhibiting the recognition of HIV-1 to CD4 
molecule or to the chemokine receptors CCR5 and CXCR4 in vitro [188]. Early attempts to 
find entry inhibitors include a recombinant CD4 molecule and the monoclonal antibody 
ibalizumab, which inhibit the viral attachment by directly targeting the gp120-CD4 
interaction or by preventing the subsequent gp120-CCR5/CXCR4 interaction, respectively. 
So far, the CCR5 antagonist Maraviroc has shown the most promising antiviral efficacy and 
was approved by FDA in 2007 for clinical use [189-191]. However, Maraviroc usage has 
been shown to induce the emergence of CXCR4-using viruses, which in turn have been 
correlated with decreasing CD4+ T lymphocyte count and disease progression [189, 192].  
1.5.1.2 HR1-HR2 interaction  
The development of antiviral fusion inhibitors has focused on the HRs and the 6-HB fusion 
core, the key structure within the Class I viral fusion glycoproteins that mediate the 
membrane fusion [186, 187, 193-196]. The most studied examples include the fusion 
inhibitors derived from the HRs of HIV-1 gp41. It is believed that the peptidyl derivative of 
either HR could selectively recognize and bind to the other HR within the fusion protein 
transiently exposed at the pre-hairpin intermediate stage, thereby blocking the 6-HB and 
fusion pore formation in a dominant negative manner. In support of this viral inhibition 
model, the peptidyl fusion inhibitor C34, which is derived from the gp41 HR2, formed 6-HB 
with the HR1-drived peptides [197]. The formation of the 6-HB between C34 and the HR1-
derived peptides is stabilized by two mechanisms. The C34 helix can bind along the grooves 
of the central HR1 coiled-coil [197]. This mechanism has inspired ways to enhance the anti-
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viral efficacy of C34. Salt bridges and/or sequence replacements have been introduced into 
C34 to enhance its helicity and association with Env HR1 to form a stable 6-HB, which 
thereby improves its anti-viral efficacy [185, 198-200]. The formation of a stable 6-HB and 
the potency of C34 are also contributed by the interaction between the a pocket binding 
domain (PBD) within C34 and a hydrophobic cavity located at the HR1 C-terminus [197]. 
However, the PBD-cavity interaction and a stable 6-HB is not necessary for an effective viral 
inhibition, as evidenced by the development of T20/Enfuvirtide (Trimeris, Inc. and Roche) 
which is the only licensed antiviral fusion inhibitor for clinical use. T20 is derived from the 
aa 638-673 of HR2 and lacks the PBD [187]. Consequently, it cannot inhibit viral entry 
through forming a stable 6-HB with the viral HR1 [201]. Instead, the additional MPER 
sequence, WNWF, compensates the loss of PBD by conferring T20 with the ability to bind to 
the membrane, to interfere with the oligomerization of the fusogenic gp41, and to inhibit the 
post-lipid-mixing fusion pore formation [202]. Deletion or substitution of the partial MPER 
sequence abrogated the antiviral effect by increasing its IC50 over 1000-fold [187, 201]. 
Logically, both PBD and the lipid-binding MPER sequence are included in the next 
generation of fusion inhibitor, T1249. As compared to T20, T1249 has a higher potency, 
longer half-life, and broader antiviral spectrum [203]. However, the clinical development of 
T1249 was halted due to formulation issues. While most of the peptidyl fusion inhibitors 
derived from the HRs of the Class I viral fusion glycoprotein did not reach clinic use, their 
sequence-specific recognition of the HRs to form 6-HB have made them attractive research 
reagent in mechanistic studies and vaccine development.   
1.5.1.3 MPER 
HIV-1 Env MPER is capable to oligomerize under lipidic environment, and it also interacts 
with the N-terminal FP regions putatively post-6-HB formation [168]. The N-terminal MPER 
sequence WNWF has further been shown to be essential for the antiviral activity of T20, 
putatively by conferring T20 with membrane reactivity. It was logical to expect that the 
peptidyl derivative of MPER could bind to the viral MPER and/or other interacting ligands 
and hence halt fusion pore formation and viral entry. The high level of sequence conservation 
of the MPER further makes it an attractive target for the development of novel peptidyl 
fusion inhibitors. Peptide C8, a MPER-derived peptide of feline immunodeficiency virus 
(FIV) could inhibit the infection of 12 primary FIV strains with IC50 values of 0.03-0.63 
ug/ml [204]. Retro-inversion of C8 by reversing the sequence and replacing all the residues 
with D-amino acids further enhanced the peptide stability while preserving the antiviral 
activity [205]. However, the anti-viral mechanistic study of the MPER or MPER-containing 
peptides have mainly focused on the N-terminal sequence and/or the Trp residues, and the 
potential contribution of the CRAC motif in viral inhibition has not been discussed.   
1.5.1.4  The future of peptidyl antivirals derived from the Class I viral fusion 
glycoproteins 
Despite of the progress and success in developing entry/fusion inhibitors, they are constantly 
challenged by the emergence of drug-resistant viral strains, poor bioavailability and 
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formulation issues, which collectively contribute to patient non-adherence and virological 
failures [206-209]. These issues could be potentially circumvented by employing structure-
based design to enhance the helicity of the HR-derived peptides that promotes their formation 
of 6-HB with the viral HRs [185, 200, 210], by attaching lipid-interacting groups such as 
fatty acid tail and cholesterol to concentrate the drugs to viral entry sites [211-213], by 
conjugating the peptides to a serum-stable molecules to enhance their stability [214], or by 
introducing the protease-resistant D-amino acids to the peptides [205, 215, 216].  
Nevertheless, novel targets for developing antivirals and biochemical reagents are always 
needed, particularly when facing genetically evolving viral pathogens such as HIV-1, 
pathogens without effective treatment such as SARS-CoV, and emerging pathogens such as 
MERS-CoV. This thesis focuses on identifying novel interaction-mediating sequences within 
Class I viral fusion glycoproteins, investigating their potential involvements in viral 
infectivity, and on developing these sequences as anti-viral therapeutics and virus detection 
agents.  
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2 AIMS OF THE THESIS 
The main objective of this thesis was to identify novel interaction-mediating sequences 
within Class I viral fusion glycoproteins, to study their implications in viral entry and 
infectivity, and to potentially apply them for viral detection and therapeutic interventions. 
Specifically,  
 
 to identify the self-binding sequences that interacted through self-complementary zipper-
like motifs within the SARS-CoV S protein and to develop them as virus detection 
reagents; (Paper I) 
 
 to investigate the putative interaction(s) mediated by the SARS-CoV S protein MPER 
during viral entry; (Paper II) 
 
 
 to study the invovlement of the membrane-active sequence elements within the HIV-1 Env 
MPER during viral entry and assembly, specifically in the design of MPER-based fusion 
inhibitors and in the biosynthesis of viral structural proteins; (Paper III) 
 
 and to examine the post-ER-targeting influence of the HIV-1 Env ss in the viral 
replication. (Paper IV)  
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3 METHODOLOGICAL CONSIDERATIONS  
In this section, general considerations are presented about materials and methods. Details 
about reagents and methods are described in the separate papers (I-IV). 
3.1 FRAGMENT-BASED PEPTIDE ARRAY SCANNING  
In peptide array scanning, rationally chosen or combinatorially generated peptide libraries are 
synthesized onto individual spots on a planar solid support (e.g. a membrane), and are then 
probed with solutions of a target protein [217, 218]. By synthesizing and probing peptides in 
the spatially addressable spots in parallel, peptide array scanning provides a high-throughput 
means to identify protein-protein or protein-ligand interactions. It has a broad spectrum of 
applications including antibody-peptide binding assays, proteomic studies and diagnostic 
assays [217-224]. Previously, peptide array scanning has also been applied to identify the 
protein regions that are involved in homotypic interactions or self-association, where 
overlapping peptides were probed with the cognate protein in solutions [225-228]. These 
studies inspired the choice of peptide array scanning to identify self-binding peptides within 
the S protein of SARS-CoV. To identify the self-binding peptides, overlapping S protein-
derived peptides were synthesized on a PEG-derivatized cellulose membrane and then probed 
with a HA-tagged S protein ectodomain named S1188HA. The peptide spots that retained 
S1188HA were then identified by anti-HA chemiluminescence (Paper I). 
A peptide array library can be prepared on a solid support either by the so-called SPOT 
technology [229, 230] or by photolithography [231]. The former is widely used and was also 
employed in this study. The SPOT technology involves delivery of small amounts of reagents 
to each spot position, which allows the individual peptides to be locally synthesized within 
each spot by solid-phase synthesis. The N-terminal amino acid is anchored onto the 
membrane and then the N-terminus to C-terminus elongation is performed using the 
Fmoc/tBu-chemistry. The simplicity of the SPOT technology in the simultaneous synthesis 
and anchorage of the peptide arrays, however, precludes the purification or identification of 
the synthesized peptides. Peptides up to 15 aa could be SPOT-synthesized with comparable 
purity as by the solid-phase peptide synthesizers, i.e. 70 to 90% purity [232]. Generally, the 
peptide purity decreases with increasing peptide length, although with optimization peptides 
of 34 aa could also be SPOT-synthesized up to 65% purity [233]. Nevertheless, to minimize 
differential S protein-binding efficiency due to different purities and/or amounts of peptides 
in different spots, the peptide array libraries in Paper I were constructed to contain peptides 
of 15 to 20 aa. Peptide arrays offer semi-quantitative readouts, allowing avidity of the 
peptide-protein interaction to be deduced from the spot intensities. Still, the identified 
interaction-mediating peptides need to be confirmed through other biochemical means. 
Hence, the S protein-binding peptides identified by peptide array were synthesized by regular 
solid phase synthesis using Fmoc chemistry and confirmed via pull down assays employing 
S1188HA. 
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3.2 AMYLOID-LIKE FIBRILLATION PREDICTION AND BIOCHEMICAL 
DETERMINATION  
Cross-β spine steric zipper motif, or simply steric β-zipper, is the central motif in mediating 
the formation of amyloid-like fibrils. Steric β-zipper peptides derived from the amyloidogenic 
proteins have been shown to bind to the fibrillation site specifically and to effectively obstruct 
the protein aggregation [234]. To apply sequence specific interaction, offered by the steric β-
zipper, to viral detection, potential steric β-zipper-like sequences within the S protein were 
first predicted by the 3D profile method in Paper I.  
The 3D profile method was first described as a general scheme to predict the potential of a 
given aa sequence to fold into a certain 3D structure [235]. By considering the local 
environment of each residue, and not just the isolated aa properties, the 3D profile method is 
a structure-based prediction algorithm. In this method, each residue within a known 3D 
structure is classified into one of 18 environmental classes, which summarize the residue’s 
buried/inaccessible area, side chain area that is covered by polar atoms, and local secondary 
structure. By studying a library of known protein 3D structures, the occurrences or 
preferences of each aa in different environmental classes are then obtained. Thereby, the 
propensity of a sequence to adopt a given structure could be deduced from the likelihood of 
the residue at a certain position of that sequence to be present in the specific environmental 
class at that position in the given structure. Following the same principle, the 3D profile 
method was developed to predict amyloidogenic peptides. Specifically, it predicts the 
propensities of hexamer peptides to adopt the cross-β spine steric zipper structure of the 
amyloidogenic peptide NNQQNY [236-239]. Using this method, the prediction accuracy has 
been reported to be over 80% [239]. Nevertheless, biochemical studies such as Congo Red- 
and Thioflavin T (ThT)-binding spectroscopy studies are needed to confirm the abilities of 
the positively predicted peptides to form amyloid-like fibrils.   
The ability to bind to Congo Red is considered to be one of the definitive characteristics of an 
amyloid-like fibril [240]. Upon binding to Congo Red, amyloid-like fibrils further exhibit 
apple green birefringence under polarized light. The Congo Red birefringence assay has been 
extensively applied to detect amyloid-like fibrils. However, many things including human 
hair could exhibit birefringence under polarized light and this assay could be subjective [240]. 
The Congo Red spectroscopic assay, which relies on the absorbance difference at 540 nm 
upon Congo Red-binding, offers a more objective means to identify amyloid-like fibrils 
[240]. The ThT-binding spectroscopic assay relies on the binding of amyloid-like fibrils to 
ThT, and can be further used to estimate the kinetics of the amyloid-like fibrillation [240]. 
The ThT-binding and Congo Red spectroscopic assays were employed in Paper I to confirm 
the amyloid-like fibrillation of S protein-derived peptides.  
3.3 CIRCULAR DICHROISM SPECTROSCOPY  
An optically active or chiral molecule absorbs the left-handed circularly polarized light and 
the right-handed circularly polarized light differently, a phenomenon termed circular 
dichroism (CD). CD spectroscopy measures the CD of a given molecule over a range of 
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wavelengths, and is widely used to determine the secondary structures of peptides/proteins. 
Different peptide/protein secondary structures have their characteristic CD spectra. For 
example, an α-helix exhibits dual minima at 208 nm and 222 nm and a single maximum at 
193 nm, while a β-sheet exhibits a single minimum at 218 nm and a maximum at 195 nm. 
Most often, peptides or proteins contain a mixture of secondary structures and each structural 
component could be estimated by fitting the obtained CD spectra with the CD spectra of 
molecules with known structure. In Papers I, II and III, to estimate their secondary 
structures, the peptides were subjected to CD spectroscopy. Their CD spectra were 
subsequently de-convoluted with the CDSSTR de-convolution algorithm on Dichroweb, 
where the goodness-of-fit parameter, or NRMSD (normalized root mean square deviation), 
was set to be equal to or below 0.15 [241-243]. 
In Papers II and III, MPER-derived peptides were studied. Considering the membrane-
proximal location of the MPER within the Class I viral fusion glycoproteins and their 
potential interaction with the membranes, secondary structures of the MPER-derived peptides 
were studied in a hydrophobic environment. Although the specific mechanism is still in 
dispute, 2,2,2-trifluoroethanol (TFE) has been known to stabilize native peptide structures 
and has therefore been considered to be a model system for a membrane-like environment 
[244]. Therefore, in Papers II and III the MPER-derived peptides were dissolved in buffers 
supplemented with increasing concentrations of TFE. 
3.4 CHEMICAL CROSSLINKING 
Protein-protein interactions could be stably organized multi-protein complexes or transient 
encounters. Transient protein-protein interactions are difficult to detect and define. 
Introduction of stable chemical linkage between the transiently interacting proteins is a direct 
way to demonstrate unambiguously a protein-protein interaction. Chemical crosslinkers 
contain two or more reactive ends that are capable of covalently linking two proteins when in 
close proximity. Thus, crosslinkers serve as useful tools in identifying transient protein-
protein interactions [245]. Chemical crosslinkers can be divided into several classes based on 
their reaction groups, differences in the chemical specificities of their two reactive ends, their 
water-solubility and ability to be selectively activated. Glutaraldehyde is an amine-reactive 
homobifunctional crosslinker, meaning that it contains two identical reactive ends, which 
react with the ε-amino groups of lysine residues and the primary amines on the N-termini of 
the target protein. It is a popular crosslinking reagent, as it is soluble in aqueous solvents and 
is able to form stable inter- and intra-subunit covalent bonds. In Papers I and II, 
glutaraldehyde was used to crosslink the S protein-derived peptides, to study the potential 
self-oligomerization of these peptides and the interaction between the S protein MPER and 
IFP. Peptides were incubated with glutaraldehyde for 1 h at room temperature. The reactions 
were quenched by 100 mM glycine. Peptide oligomers were analyzed by gel electrophoresis 
and Western blot. The relatively high prevalence of amine groups within proteins and 
peptides might result in non-specific chemical crosslinking by glutaraldehyde. To exclude 
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connections between proteins that were in proximity but not reacting with one-another, 
negative control peptides were included in the crosslinking experiments. 
3.5 WESTERN BLOT  
Western blot is a standard peptide/protein analysis method. In Western blot, the proteins are 
separated by gel electrophoresis and then transferred to a membrane, which thereafter is 
blocked with blocking solution usually containing a mixture of unrelated proteins. The 
proteins to be analyzed are stained with target-specific antibodies [246]. The antibody 
binding is detected with a reporter molecule conjugated either directly onto the target-protein-
specific primary antibody, or onto the species-specific secondary antibody targeting the 
primary antibody. The most common reporter molecule is horseradish peroxidase, which 
oxidizes a chemiluminescent reagent in the detection solution such as luminol to 3-
aminophthalate, thereby releasing light for detection. In Papers I, II, III and IV, Western 
blot was used for the detection of biotinylated peptides, HA-tagged S protein ectodomain 
S1188HA, β-actin and HIV-1 viral proteins including Env, Vif, p55/Gag, p24/Capsid, 
p160/Gag-Pol and Nef. Protein concentrations of the observed bands in the Western blots 
may be quantified with high reproducibility by carefully establishing standard curves [247]. 
However, due to the low-dynamic range of detection and the difficulty to determine the 
detection limit, Western blot band densities are largely regarded as semi-quantitative. In this 
thesis, the protein/peptide band intensities were quantified by ImageJ, and were further 
normalized to the band intensity of a cellular control protein, such as β-actin or that of the 
WT viral protein. 
3.6 PSEUDOTYPED HIV-1 SYSTEM AND THE VIRAL INHIBITION ASSAY 
A pseudotyped virus is constructed by combining incomplete but complementing viral 
vectors from two different viruses, or where one of the vectors is mutated but from the same 
virus [248]. When a mutated envelope/capsid protein is introduced into a pseudotyped virus, 
it alters the host tropism or changes the stability of the virus particles [248]. Pseudotyped 
virus particles from the transfected cells can enter and infect cells. The progeny pseudotyped 
viral particles generated by the infected cells, however, do not contain the vector(s) encoding 
the viral structural protein(s), rendering them replication incompetent, i.e. non-infectious 
[248]. This single-replication-cycle property of pseudotyped virus is particularly useful for 
studying the viral entry process and to test the anti-viral efficacy of entry/fusion inhibitors, 
being independent from other steps of the viral replication cycle [249].  
In Paper III, pseudotyped HIV-1 particles were used to test the Env MPER-derived peptides 
as entry/fusion inhibitors. The pseudotyped HIV-1 particles were constructed by co-
transfecting HLtat cells [250, 251] with pNLHIVΔuΔss and pNL1.5EU+. The NL4-3 strain 
proviral construct pNLHIVΔuΔss contains a mutation in the vpu start codon and a truncation 
of the Env ss region, which prevent the expression of functional Vpu and Env and the 
production of infectious viral particles [252, 253]. Meanwhile, pNL1.5EU+ contains the 
LTR-driven exon 1 and exon 5 of HIV-1(NL4-3) transcript that encode the viral Vpu, Env 
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and Nef proteins [121]. Expression of Rev from pNLHIVΔuΔss boosts the expression of Vpu 
and Env from the unspliced transcript of pNL1.5EU+, which complement the viral-like 
particles produced from pNLHIVΔuΔss and enable them to enter and infect the CD4+, 
CCR5+ target cells [121]. The infectivity of the resulting pseudotyped HIV-1 particles were 
confirmed in the CD4+, CCR5+ TZM-bl cells that contain copies of LTR-driven luciferase 
and ß-galactosidase genes [208, 254-257].  
The minimal region required for autonomous HIV-1 RNA packaging during viral assembly is 
mapped to a region covering the first 350-400 nt of the genome, spanning the LTR and the 5’ 
part of gag gene [258-262]. This means that even if pNL1.5EU+ contains the LTR promoter 
and the viral packaging (ψ) signal, its unspliced Env-encoding transcript under the LTR 
promoter is unlikely to be packaged into the budding virions effectively. Furthermore, 
production of genomic RNA dimers, which is essential for infectious virus production, 
requires two complete copies of the genomic RNA [263]. Taken together, the pseudo-typed 
HIV-1 viral particles generated in this study could unlikely generate Env-positive infectious 
progeny virus particles. The single-replication-cycle property of the constructed pseudotyped 
HIV-1 particles was confirmed by their loss of infectivity when the culture supernatant of the 
infected TZM-bl cells was re-applied to a new dish of TZM-bl cells.     
In the viral inhibition assays of this thesis, effective concentrations of peptides inhibiting 50% 
(IC50) and 80% (IC80) of the viral infectivity were estimated from the dose-response curves 
generated with the sigmoidal dose-response non-linear regression model on Prism GraphPad 
software. 
3.7 REAL TIME QUANTITATIVE POLYMERASE CHAIN REACTION (RT-QPCR) 
Polymerase chain reaction (PCR) was first introduced in 1983 by Kari Mullis [264]. It has 
been a powerful tool in the selective amplification, quantification and sequential analysis of 
DNA samples. In Paper IV, a PCR method that reports the quantity of the amplified product 
in real time (real time (RT)-qPCR) was employed to quantify the full-length HIV-1 viral 
transcripts.  
For the RT-qPCR, total RNA was extracted from the cell lysate, reverse-transcribed into 
cDNA, and then amplified in the presence of a pair of target gene-specific primers and a 
DNA-binding reporter dye/probe. The DNA-binding reporter dye/probe provides the basis of 
real-time detection of the amplified product. It is a stretch of gene-specific nucleotides linked 
with a reporter fluorescent dye on one end and a quencher on the other, commercially known 
as the TaqMan probe. When intact, the quencher molecule inhibits the fluorescence from the 
reporter. The gene-specific nucleotides are chosen so that the probe will bind within the 
intended amplicon of the target gene cDNA. During the amplification, as the polymerase 
machinery proceeds to the probe-binding site, the quencher molecule will be cleaved off the 
probe. This results in an increase of the fluorescence signal that is detected by the machine. 
Alternatively, a SYBR green system-based dye, which binds only to the double-stranded 
DNA amplification product, could be used in place of the TaqMan probe. While SYBR green 
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is a cheaper way to set up the RT-qPCR experiments, TaqMan offers lower false positive 
signals. In this thesis, RT-qPCR was performed with the TaqMan chemistry.  
The quantification can be done with two different methods, an absolute or a relative 
quantification. The absolute quantification determines the copy number of the target gene 
transcript directly, but requires the construction of standard curves. The relative 
quantification describes the changes in the copy number of the target gene transcript in 
relation to that of a house-keeping or reference gene transcript. It is more convenient to set 
up, but requires comparable polymerase reaction efficiencies between different genes. In this 
thesis, the full-length HIV-1 transcript was quantified using the relative expression analysis 
based on the 2-ΔΔCt method, with the human glyceraldehyde 3-phosphate dehydrogenase 
(hGAPDH) as the reference gene [265].  
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4 RESULTS 
4.1 PAPER I 
IDENTIFICATION AND APPLICATION OF SELF-BINDING ZIPPER-LIKE 
SEQUENCES IN SARS-CoV SPIKE PROTEIN.  
 
STUDY BACKGROUND 
Self-binding peptides containing zipper-like sequences, such as the Leu/Ile zipper sequence 
within the coiled coils and the cross-β spine steric zippers within the amyloid-like fibrils, 
could bind to the protein-of-origin through forming sequence-specific zipper-like motifs. 
They represent an attractive target for various biochemical applications, despite their length-
dependent and modest self-binding affinities. The cross-β spine steric zipper, or steric β-
zipper, is a complementary, dry, steric-zipper interface formed between the tightly 
interdigitating side chains of two facing peptide β-sheets of the same sequence [238, 266-
271]. It is the central motif in mediating peptide/protein to form amyloid-like fibrils and can 
be readily predicted using the 3D profile method [235-237, 239]. Previously, peptides 
containing this motif have been shown to inhibit fibrillation effectively [234]. The study in 
Paper I combines the predictive and peptide scanning methods to identify the self-binding 
sequences containing the cross-β spine steric zipper-like motif within the SARS-CoV S 
protein.  
 
Identification of the putative self-binding peptides within the S protein  
Thirty-four putative S protein-binding peptides of six clusters were identified, by scanning a 
peptide array composed of S protein-derived overlapping 20-mer peptides with S1188HA, an 
HA-tagged recombinant ectodomain of the S protein (aa 1-1188) (Figure 12A) [155]. Five of 
the six clusters of S protein-binding peptides each contained a core octapeptide consensus 
sequence, subsequently GINITNFR (aa 225-232) in Cluster I derived from the region 
upstream to the RBD, VLTPSSKR (aa 537-544) in Cluster II from the region immediately 
following RBD, LNRALSGI (aa 745-752) in Cluster III from the region upstream of the FP, 
AMQMAYRF (aa 881-888) in Cluster IV from the second fusion peptide region IFP, and, 
finally, RLITGRLQ (aa 977-984) in Cluster V from the HR1 (Figure 12B-F). The eight 
peptides of the sixth cluster R covering the β-1, -3, -4, -5 and -6 of the seven β sheets within 
the RBD, interacted with S1188HA with relatively high affinities but did not yield a core 
consensus sequence (Figure 12B) [38]. 
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Figure 12. Peptide array scanning for putative self-binding sequences within the S protein. (A) 
The S protein-binding peptides were identified by probing the S protein-derived peptide array with 
Sf9 cell-expressed S1188HA. Positive peptide-protein interactions were quantified as peaks in optical 
density value (o.d.v.). Representative peptide(s) of each cluster (I, II, III, IV, V and R) and the false 
positive peptides were indicated by asterisk the arrow heads, respectively. (B) The core sequence 
(shaded and bold) of Cluster I, (C) II, (D) III, (E) IV and (F) V. 
 
Peptide C6 containing the Cluster I core sequence self-interacted and formed amyloid-
like fibrils 
The 3D profile prediction [237, 239] indicated that the hexapeptide GINITN within the 
Cluster I core sequence had a high propensity of fibrillation through the steric β-zipper motif 
(Figure 13C). The mechanism of the interaction between S1188HA and the Cluster I 
representative peptide C6 was further elucidated. Despite SARS-CoV S protein is heavily 
glycosylated with 23 potential N-linked glycosylation sites [272], C6 pulled down N-
deglycosylated S1188HA from the Sf9 cell lysate as effectively as pulling down the untreated 
S1188HA (Figure 13A). This suggests that the C6-S protein interaction was likely mediated 
by sequence-specific interactions. Furthermore, C6 trimerized, as did the control peptide 
GG38, which was derived from the trimerizing HR2, under increasing concentrations of the 
chemical crosslinker glutaraldehyde (Glut) (Figure 13B) [46, 50, 273]. Finally, peptide C6 
was subjected to CD spectroscopy for secondary structure determination and to amyloid-like 
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fibrillation assays (Figure 13C). De-convolution of the CD spectrum of C6 revealed a 
relatively high β-strand content (~36%) under aqueous conditions (Figure 13C). C6 further 
formed amyloid-like fibrils as determined by an increase in absorbance at 540 nm upon 
binding to Congo Red, and an increase in florescence emission at 482 nm upon binding to 
ThT (Figure 13D-E). The data obtained suggest that part of C6 could form steric β-zippers, 
the common structural motif within amyloid-like fibrils [236, 238]. They further indicated 
that C6 could self-interact with the same sequence within the S protein through a β-zipper-
based interaction.  
 
 
Figure 13. Peptide C6 containing cluster I core sequence could self-interact. (A) Peptide C6 
pulled down N-deglycosylated S1188HA expressed in Sf9 cells. (B) Peptide C6 trimerized under 
chemical crosslinking using glutaraldehyde (Glut). (C) Cluster I core sequence (shaded) within 
peptide C6 was predicted to contain an amyloid-like fibril-forming hexapeptide (underlined). Peptide 
C6 exhibited relatively high β-strand content in ddH2O. NRMSD, normalized root mean square 
deviation. (D) Peptide C6 (10mg/ml) in DMSO was accessed for amyloid formation by Congo Red 
and by (E) Thioflavin T (ThT) spectroscopic assays. 
 
Self-interacting peptide C6 detected the S protein expression and homodimerization 
enhanced its affinity to S1188HA 
Taking advantage of the sequence-specific self-interacting property of the steric β-zipper 
motif, C6 was used to detect the S protein expression via immunofluorescence staining. In the 
293T cells transiently expressing an HA-tagged full-length S protein, the detection signal of 
peptide C6 at 2µM followed by the Dylight 488-conjugated NeutrAvidinTM overlapped with 
the signal of an rabbit-raised anti-HA antibody as the primary antibody followed by an Alexa 
Fluor 594-conjugated anti-rabbit secondary antibody (Figure 14A). However, the overlapping 
detection signal by C6 and the anti-HA antibody could be due to an interaction between C6 
and the anti-HA antibody. To exclude this possibility, the 293T cells, expressing the un-
tagged full-length S protein (S1255) were either stained with peptide C6 at 2µM followed by 
Dylight 488-conjugated NeutrAvidinTM or with a conventional mouse-raised anti-S protein 
  33 
monoclonal antibody followed by an Alexa Fluor 488-conjugated anti-mouse secondary 
antibody. The staining pattern and intensity of C6 and anti-S antibody were similar (Figure 
14B).  
Homodimerization of C6 through a lysine-based linker further enhanced the C6-S1188HA 
interaction avidity (Figure 14C-D). In a pull down assay, the dimeric C6 peptide, C6-D, 
pulled down approximately 2.5 times higher amount of S1188HA than C6 did.  
 
 
Figure 14. Peptide C6 detected S protein expression and the C6-S protein interaction could be 
enhanced through dimerization. (A) The detection signal of C6 overlapped with that of anti-HA 
antibody in the 293T cells transiently expressing an HA-tagged full-length S protein. (B) 
Immunoflorescence staining of 293T cells transiently expressing an untagged full-length S protein 
using C6 yielded similar staining intensity and pattern as when using an anti-S monoclonal antibody. 
(C) Lys-based linker molecule for the synthesis of C6-D. (D) C6-D pulled down approximately 
double amount of S1188HA than C6 did in pull down experiment.  
 
Effects of peptide lengths in identifying helix-mediated interactions 
The HR-derived peptides, which have been previously shown to oligomerize, were under-
represented in the peptide array scanning. S1188HA pull-down experiment using twenty-five 
HR2 peptides of different lengths suggest that the 20-mer peptides in the peptide arrays could 
not attain high-affinity helix-mediating interactions such as between the HR sequences. The 
recombinantly-produced HR2 peptides, MBP-n, were constructed with an N-terminal maltose 
binding protein (MBP) followed by n (11 to 35) aa of HR2 sequences. MBP-30 to MBP-35 
containing near-full-length HR2 sequences of over 30 amino acids pulled down S1188HA 
with high efficiency, with the exception of MBP-31(Figure 15). Further truncation 
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diminished the pull down activity of the MBP-n, with the exceptions being MBP-16 to MBP-
21 containing approximately half of the HR2 sequences. However, they were significantly 
less efficient in pulling down S1188HA than the near-full-length HR2 peptides. 
 
 
Figure 15. S1188HA pull-down experiment with MBP-n constructs. S1188HA in SF9 cell lysate 
was pulled down by MBP-HR2-n fusion proteins (n = 11-35), with the resin only or MBP only served 
as the negative controls.  
 
 
4.2 PAPER II 
TRYPTOPHAN-DEPENDENT MEMBRANE INTERACTION AND 
HETEROMERIZATION WITH INTERNAL FUSION PEPTIDE BY 
MEMBRANE PROXIMAL EXTERNAL REGION OF SARS-COV SPIKE 
PROTEIN   
  
STUDY BACKGROUND 
During viral entry mediated by Class I viral fusion glycoproteins, the formation of the 6-HB 
fusion core approximates the regions flanking HR1 and 2. In SARS-CoV S protein, they are 
the FP and IFP, upstream to HR1, and the MPER, downstream of HR2. Peptide array 
scanning for S protein sequences involved in homotypic interactions in Paper I identified 
three IFP-derived peptides. Meanwhile, the FP-derived peptides were only identified upon 
heat denaturation of the S protein, suggesting different positioning and potential interaction 
partners of these two hydrophobic regions within the S protein. Furthermore, peptide 
scanning in Paper I used the S protein ectodomain, S1188HA, excluding the MPER and 
beyond. In Paper II, the potential of SARS-CoV S protein MPER to oligomerize and 
heteromerize with the FP regions was examined, and the roles of the highly conserved Trp 
residues in maintaining these processes were further investigated.  
 
Trp residues were essential for the oligomerization of the S protein MPER  
Among the peptides derived from the SARS-CoV S protein MPER, the peptide designated 
M-wt contained the wild type (WT) MPER sequence, and the peptides M-3W3A and M-
  35 
3W3F contained MPER sequences with triple TrpAla or Trpphenylalanine (Phe) 
substitutions (Table 4). 
 
Table 4. Peptides derived from the coronavirus S proteins. 
Peptides Virus Region (aa) Sequence 
M-wt SARS-CoV MPER (1187-1202) KYEQYIKWPWYVWLGF 
M-3W3A SARS-CoV MPER (1187-1202) KYEQYIKAPAYVALGF 
M-3W3F SARS-CoV MPER (1187-1202) KYEQYIKFPFYVFLGF 
M-ibv IBV MPER (1186 -1202) LKTYIKWPWYVWLAIAF 
FP19 SARS-CoV FP (770-788) MYKTPTLKYFGGFNFSQIL 
IFP23 SARS-CoV IFP (866-888) AGWTFGAGAALQIPFAMQMAYRF 
TE20 SARS-CoV (743-762) TQLNRALSGIAAEQDRNTRE 
 
Under chemical crosslinking using glutaraldehyde, the WT MPER-derived peptide M-wt 
formed trimers and higher-order oligomers, while Ala-substituted peptide M-3W3A did not 
(Figure 16). Phe-substituted peptide M-3W3F retained the ability to oligomerize, suggesting 
that aromatic side chains were essential for the MPER-MPER interaction. However, instead 
of a discrete order of oligomers as in M-wt, M-3W3F formed a continuous band of 
oligomers.  
 
Figure 16. The S protein MPER-derived 
peptides oligomerized. Oligomerization 
of M-wt, M-3W3A and M-3W3F were 
accessed under 0, 1 or 5 mM 
glutaraldehyde (Glut).  
 
 
 
Trp residues were essential for the heteromerization between the MPER- and IFP-
derived peptides  
Addition of M-wt to the biotinylated IFP-derived peptide IFP23b (Table 4) induced the 
formation of peptide dimer, trimer and higher-order oligomers, under chemical crosslinking 
(Figure 17A). Meanwhile, no peptide oligomers were formed when co-incubating M-wt with 
the biotinylated FP-derived peptide FP19b, nor with peptide TE20b, which was derived from 
an FP-proximal region (Figure 17A). This induced peptide oligomer formation was abrogated 
in the IFP23b/M-3W3A mixture, and restored in the IFP23b/M-3W3F mixture (Figure 17B).  
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Figure 17. The S protein MPER-derived peptide M-wt heteromerized with the IFP-derived 
IFP23b, in a Trp-dependent manner. (A) Addition of M-wt induced the formation of hetero-
oligomers between M-wt and IFP23b, as accessed by chemical crosslinking using glutaraldehyde 
(Glut). (B) Substitutions of the Trp residues within M-wt with Ala inhibited the formation of M-wt-
IFP23b hetero-oligomer.  
 
The MPER of various Class I fusion glycoproteins have been characterized as a membrane-
active region, capable of membrane partition and lipid mixing [43, 142-144, 158-161, 166, 
274]. Here, immunofluorescence staining of the cells that were treated with biotinylated 
MPER-derived peptides revealed that M-wtb signal co-localized with the lipid raft marker 
GM1 gangliosides (Figure 18A). The Ala substitutions abrogated the lipid-raft-binding of 
peptide M-3W3Ab and the Phe substitutions partially rescued the phenotype (Figure 18A).  
Furthermore, co-application of M-wt and IFP23b to Vero E6 cells facilitated the recruitment 
of IFP23b, which was rarely detected when applied alone, to the cell membrane lipid rafts 
(Figure 18B). It suggests that the MPER- and IFP-derived peptides could form non-covalent 
complexes under a relatively physiological-relevant condition as compared to chemical 
crosslinking. No increase in the IFP23b signal was observed in cells treated with IFP23b/M-
3W3A, confirming the inability of IFP23b to bind to M-3W3A (Figure 18B). In contrast, an 
increase of the IFP23b signal was observed in cells treated with IFP23b/M-3W3F, 
highlighting that M-3W3F recovered the IFP23b-binding ability (Figure 18B).  
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Figure 18. Immunofluorescence staining confirms the Trp-dependent heteromerization between 
M-wt and IFP23b. (A) Exogenously applied M-wtb bound to plasma membrane lipid rafts but not its 
Ala-substituted analogue M-3W3Ab. (B) M-wt enabled the translocalization of IFP23b onto the 
plasma membrane lipid rafts, potentially through the M-wt-IFP23 interaction.  
 
Synthetic MPER-derived peptides inhibited coronavirus entry and infection in a dose-
dependent manner 
M-wt inhibited the entry and infection of IBV, which contains a highly similar S protein 
MPER sequence as in SARS-CoV, in a dose-dependent manner (Figure 19). The peptide 
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derived from the IBV MPER, M-ibv (Table 4), exhibited a similar level of inhibition. 
Meanwhile, the triple TrpAla substitutions in M-wt abrogated the antiviral efficacy of the 
peptide, it rather promoted the viral infectivity (Figure 19).  
 
 
Figure 19. M-ibv and M-wt inhibited 
IBV-Luc infection in Vero E6 cells in 
a dose-dependent manner.  
 
 
 
4.3 PAPER III 
MEMBRANE-ACTIVE SEQUENCES WITHIN GP41 MEMBRANE PROXIMAL 
EXTERNAL REGION (MPER) MODULATE MPER-CONTAINING PEPTIDYL 
FUSION INHIBITOR ACTIVITY AND THE BIOSYNTHESIS OF HIV-1 
STRUCTURAL PROTEINS 
 
STUDY BACKGROUND   
In Paper II, SARS-CoV S protein MPER-derived peptides inhibited the coronavirus entry 
and infection in a dose-dependent manner. Paper III further explored the anti-viral 
application of the MPER sequence but in the context of HIV-1. Previously, a partial N-
terminal HIV-1 MPER sequence (WNWF) has been suggested to contribute to the anti-viral 
activities of T20 and T1249, two anti-HIV-1 fusion inhibitors, through conferring the 
peptides with membrane-reactivity [187, 201, 202, 275-277]. Paper III investigated the roles 
of two highly conserved membrane-active sequential elements, the local enrichment of Trp 
and the C-terminal CRAC motif LWYIK [133, 151, 152, 163, 165-167, 278, 279] (Figure 
20), in the anti-viral activities of the short MPER-derived fusion inhibitor peptides. The 
fusion glycoproteins are synthesized as type I transmembrane proteins and are matured 
through the secretory pathway, a process that involves multiple membrane-interactive steps. 
In Paper III, we further studied the roles of the membrane-active sequences of the HIV-1 
Env MPER during the biosynthesis of the viral structural proteins. 
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Figure 20. Sequence alignment of the MPER-derived fusion inhibitor peptides and the Env 
MPER from different groups of HIV-1.  
 
The MPER-derived peptides required the membrane-active sequences to inhibit the 
pseudo-HIV-1 (NL4-3) infection 
At 8.0 μM and 12.3 μM peptide LK21, containing exclusively the MPER sequence, inhibited 
viral entry and thereby infectivity by 50% and 80%, respectively (Figure 20) (Table 5). N-
terminal extension of LK21 and, thus, inclusion of the HR2 residues, generating the peptide 
QK26, decreased the IC50 and IC80 values. Further N-terminal extension, resulting in EK30 
and EK37 did not enhance the anti-viral efficacy further. In contrast, deletion of the C-
terminal sequence, NWLWYIK, containing the CRAC motif LWYIK from the most active 
peptide QK26, abrogated the antiviral activity (Table 5). The abrogation of antiviral efficacy 
was also observed when the five Trp residues within peptide LK21 were substituted by Ala 
(Table 5).  
 
Table 5. Effective concentrations of the MPER-derived peptides to inhibit 50% (IC50) or 80% (IC80) 
of the pseudotyped HIV-1 infection.  
Peptides IC50 (µM) IC80 (µM) 
LK21 8.0 12.3 
QK26 3.9 8.8 
EK30 5.9 18.5 
EK37 3.1 12.6 
QT19 >33.3  
LK21-5W5A >33.3  
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N-terminal dimerization of the MPER-containing peptides selectively enhanced viral 
inhibition 
Addition of the HR2 hydrophilic residues to the MPER peptidyl analogue, LK21, greatly 
enhanced the solubility of the resulting peptides QK26, EK30 and EK37, allowing for peptide 
dimerization to possibly enhance their anti-viral efficacies. N-terminal dimerization of the 
MPER-containing peptides, EK30 and EK37, through a serine- and lysine-based linker 
showed beneficiary effect on their antiviral potencies. The N-terminal dimers (-DN), EK30-
DN and EK37-DN, had IC50 values of 1.1 μM and 1.2 μM, an increase of the potency by 5.2- 
and 2.3-fold compared to the monomeric EK30 and EK37, respectively (Table 6). In contrast, 
the C-terminal dimers (-DC) of EK37 and QK26, EK37-DC and QK26-DC, had their IC50 
values elevated by 1.4- and 1.3-fold, compared to the respective monomeric peptides (Table 
6).  
 
Table 6. Effective concentrations of the monomeric and dimeric MPER-containing peptides to inhibit 
50% (IC50) or 80% (IC80) of the pseudotyped HIV-1 infection.  
Peptides IC50 (µM) IC80 (µM) 
QK26 2.4 6.3 
QK26-DC 3.2 8.7 
EK30 5.7 16.8 
EK30-DC 2.6 >33.3 
Ek30-DN 1.1 4.9 
EK37 2.8 11.6 
EK37-DC 4.0 >33.3 
EK37-DN 1.2 5.1 
 
Trp residues maintained the structural plasticity of the MPER peptidyl analogue, LK21 
The secondary structures of the peptides LK21 and LK21-5W5A were determined by circular 
dichroism, along with the α-helical control peptide HR2-S derived from the SARS-CoV S 
protein HR2 region [280]. 10% – 40% of TFE was used to mimic the increase in 
environmental lipidity, which the MPER undergoes during membrane fusion. In the CD 
spectroscopy study, LK21 exhibited α-helical contents of 41% at 10% TFE, increasing up to 
71% when with 40% TFE (Figure 21A), while LK21-5W5A exhibited an α-helical content of 
84% starting from 20% TFE (Figure 21B).  
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Figure 21. Secondary structural contents of (A) LK21 and (B) LK21-5W5A in increasingly 
hydrophobic environment.  
 
Ala substitutions of the MPER Trp residues affected viral structural protein expression 
The importance of Trp residues in maintaining the membrane reactivity and the correct 
structure of the MPER sequence indicated that the MPER Trp residues might modulate the 
Env structure and/or its interaction with plasma membranes during the biosynthesis of Env. 
Ala substitutions of the all five Trp, the three N-terminal Trp (W664, W668 and W670) or the 
two C-terminal Trp (W676 and W678) of the MPER within a pseudotyped HIV-1 (NL-43), 
decreased the intracellular Env levels to 60% of that in HIV(WT) at 48 h post-transfection 
(Figure 22A).  
More interestingly, Ala substitutions of the three N-terminal MPER Trp residues significantly 
elevated the expression of p55/Gag, resulting in a higher p24/capsid level. At 48 h post-
transfection, intracellular p55/Gag and p24 levels in cells producing HIV(W3A) were 93 % 
and 230% higher compared to HIV(WT), while the expression of two other viral proteins Vif 
and Nef stayed unaffected (Figure 22A). Furthermore, the precipitated HIV(W3A) viral 
particles contained 200 % and 310 % higher levels of p55/Gag and p24/capsid, respectively, 
as compared to HIV(WT) particles that were precipitated from equal volume of cell culture 
supernatant (Figure 22B). This also indicated that HIV(W3A) viral particle production was 
increased as a result of the higher intracellular p55/Gag expression.  
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Figure 22. Ala substitutions of the 
MPER Trp residues affected the 
expression and viral incorporation 
of Env and p55/Gag. (A) At 48 h 
post-transfection, lysates of cells 
expressing HIV(WT), HIV(W5A), 
HIV(W3A) and HIV(W2A) were 
studied for the levels of Env gp41, 
p24/capsid, Vif, Nef and β-actin. (B) 
Env gp41, p55/Gag and p24/capsid 
levels in HIV(WT), HIV(W5A), 
HIV(W3A) and HIV(W2A) that 
were precipitated from equal volume 
of the cell culture supernatant in A. 
Un-transfected HLtat cells served as 
negative control in A and B. 
 
 
 
 
 
 
 
4.4 PAPER IV 
THE GP160 SIGNAL SEQUENCE SUPPRESSES HIV-1 REPLICATION IN 
AN LTR-DEPENDENT MANNER 
 
STUDY BACKGROUND 
In Paper III, Ala substitutions and possible structural rearrangement within the Env MPER 
induced a significant increase in both intracellular and intraviral content of p55/Gag. Paper 
IV further demonstrated that another Trp-rich Env region, the N-terminal signal peptide (ss) 
(Figure 23), could regulate the HIV-1 replication and the expression of viral proteins, 
particularly p55/Gag.  
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Figure 23. Schematic representation of the HIV-1 Env ss and the proviral vectors containing 
WT or mutant Env ss. The amino acid sequence of the native Env ss is shown with indications of its 
hydrophilic (n), hydrophobic (h) and C-terminal (c) regions, the cleavage site for signal peptidase 
(SPase) as well as the positively (+) and negatively charged residues. 
 
The Env ss suppressed the p24/capsid expression and viral particle production 
Expression of the six mutant HIV-1 proviral constructs HIVΔuss22, HIVΔuss19, 
HIVΔuss15, HIVΔuss11, HIVΔuss5 and HIVΔuΔss that contained 22 aa, 19 aa, 15 aa, 11 aa, 
5 aa and 0 aa of Env ss, respectively (Figure 23), elevated intracellular and extracellular 
p24/capsid levels and enhanced the viral particle production as compared to the WT HIV-1, 
or HIVΔuss30 (Figure 24A-B). This suppressive effect of WT Env ss on p24/capsid 
expression became less pronounced from 18 h to 48 h post-transfection.  
 
Figure 24. The Env ss suppressed the viral p24/capsid expression. (A) HIV-1 containing truncated 
ss had higher extracellular and (B) intracellular p24/capsid levels than WT HIV-1. (C) Co-expression 
of ss30-gp160, but not ss11-gp160, suppressed the p24 production from HIVΔuss30, HIVΔuss11, and 
HIVΔu∆ss.  
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Introducing a copy of WT Env ss in trans enhanced the suppression of p24/capsid expression, 
further showing that the suppressive effect of Env ss is additive. At 18 h post-transfection, the 
expression of the WT ss from ss30-gp160, but not the 11 aa-long ss from ss11-gp160, 
suppressed the total p24/capsid production from HIVΔuss30, HIVΔuss11, or HIVΔuΔss in 
HeLa-tat-III cells (Figure 24C). The suppression of p24/capsid production was most 
pronounced when the WT Env ss was expressed from both HIVuss30 and the ss30-gp160 
(Figure 24C).  
The Env ss suppressed the expression of p55/Gag, p160/Gag-Pol and Vif 
The Env ss was found to suppress the p24/capsid levels through inhibiting the expression, but 
not the proteolytic maturation, of its precursor protein p55/Gag and p160/Gag-Pol. At 48 h 
post-transfection, the intracellular p55/Gag and p160/Gag-Pol levels were higher in cells 
expressing HIVuss co-transfected with ss11-gp160 than co-transfected with ss30-gp160. 
Also the intracellular levels of another late HIV-1 protein, Vif, was up-regulated when the 
cells were co-transfected with HIVuss and ss11-gp160, as compared to the condition 
where HIVuss was co-transfected with the WT ss30-gp160 (Figure 25). 
 
 
Figure 25. The Env ss suppressed the expression of Vif and the p24/capsid precursor proteins, 
p55/Gag and p160/Gag-Pol. 
 
The Env ss downregulated the full-length viral RNA transcripts in a time-, dose-and 
LTR-dependent manner 
The WT Env ss was found to suppress the full-length viral RNA transcript in a time-, dose- 
and LTR-dependent manner. In cells that were co-transfected with HIVΔuΔss and constant 
amounts of Env-expressing plasmids, the full-length viral RNA transcript in the presence of 
either ss30-gp160 or ss11-gp160 started out to be equal at 8 h post-transfection (Figure 26A). 
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However, at 24 h and 48 h post-transfection, the RNA levels in the presence of ss30-gp160 
were lower than with ss11-gp160 by about 13% and 30%, respectively (Figure 26B-C). When 
keeping the harvest time-point at 24 h post-transfection and increasing the amount of Env-
expressing plasmids from 0.25 to 0.5 and then to 0.75 µg, the full-length viral RNA transcript 
in the presence of ss30-gp160 was 14%, 25% and finally 50% lower than that of ss11-gp160 
(Figure 26D-F). Furthermore, the expression of an LTR-driven CAT reporter molecule, in 
combination with HIVΔuΔss and ss30-gp160, was lower than its expression in combination 
with HIVΔuΔss and ss11-gp160 (Figure 26G). No significant difference in cell viability or 
total protein concentration was observed.  
 
 
Figure 26. The Env ss suppressed the full-length viral RNA transcript levels. (A) In HLtat cells 
expressing HIVΔu∆ss and ss30-gp160 or ss11-gp160, full-length viral transcript levels in the presence 
of ss30-gp160 were increasingly lower than those of ss11-gp160 from 8 h, (B) 24 h then (C) 48 h 
post-transfection. (D) When increasing the Env-expressing plasmid from 0.25 µg, (E) 0.5 µg then to 
(F) 0.75 µg, full-length viral transcript levels in the presence of ss30-gp160 was increasingly lower 
than those of ss11-gp160. ** p < 0.01 , *** p < 0.001, ***** p < 0.00001. (G) The WT Env ss 
expression inhibited the LTR-driven expression of the reporter molecule CAT enzyme. 
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5 DISCUSSION   
The viral fusion glycoproteins of enveloped viruses mediate the first steps of establishing a 
viral infection. They are considered important targets for both viral inhibition and detection. 
However, they are usually heavily glycosylated, camouflaging their functionally important 
regions from the immune system and from anti-viral interventions. Furthermore, they are 
often mutating to escape immunological attack and drug targeting. Nevertheless, some 
sequences within the fusion glycoproteins, which are involved in infection-required protein-
protein and protein-ligand interactions, are usually exposed and well preserved both 
structurally and functionally. Their structural and functional stabilities have further allowed 
peptide analogues of these sequences to be used for in vitro studies of virus-host interactions 
as well as development of anti-viral therapeutics [38, 47, 182-187].  
Class I viral fusion glycoproteins are each composed of a receptor-recognizing unit and a 
membrane-fusing unit. Within the Class I viral fusion glycoproteins, the most well-studied 
interaction-mediating sequences are the HRs within the membrane-fusing transmembrane 
unit, which are instrumental for the formation of fusion core [4]. Peptidyl analogues of the 
HRs, so far, have been the most successful peptidyl fusion inhibitors [186, 187, 193-196]. 
They inhibit the viral entry putatively through dominant-negative binding to the viral HRs, 
thereby preventing the HR heteromerization to form the fusion core. Examples include T20, a 
clinically approved anti-HIV-1 fusion inhibitor, which contains the sequence of both HR2 
and MPER of gp41 [187]. However, in drug-experienced patients, HIV-1 is constantly 
evolving, which leads to the development of virus strains that are resistant to HR fusion 
inhibitors such as T20 [208, 209]. This warrants the search for other interaction-mediating 
sequences within Class I glycoproteins, which could be targets for drug intervention. 
Furthermore, for viruses such as SARS-CoV, there is no effective treatment. Identifying such 
new target sequences would be useful for both the development of new antivirals and for the 
study of viral entry mechanism. 
In this thesis, three interaction-mediating sequences of two Class I viral fusion glycoproteins, 
the SARS-CoV S protein and the HIV-1 Env, were studied within the regions spanning from 
the extreme N-terminal signal sequence to the C-terminal MPER. The results suggested that 
they could promote viral entry at different stages, where they interact with different proteins 
and ligands such as the membranes. Their identification and potential involvements in the 
viral replication process extend our current knowledge of the Class I viral fusion 
glycoproteins-mediated viral entry and infection. 
Recognition and interaction with the viral receptor on the target cells is the first step of the 
viral entry process meditated by the Class I viral fusion proteins. In SARS-CoV S protein, a 
self-interacting sequence (C6, Paper I) containing a putative cross-β spine steric zipper motif 
GINITNFR was identified in the region spanning aa 213 to 232. The self-interaction ability of 
peptide C6 could offer some insight into the mechanisms of the SARS-CoV receptor 
recognition and its inhibition. The C6 sequence is located upstream to the RBD that interacts 
with the main viral receptor, ACE2. A previous study using pseudotyped virus has shown that 
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point mutations within this region (aa 215-232) could render the virus incapable of infecting 
the ACE2+ target cells without affecting the S protein expression [281]. Furthermore, a 
peptide derived from this region inhibits the ACE2-mediated viral entry in a dose-dependent 
manner [281]. With the region containing the C6 sequence being mapped to the exposed 
accessible region on the S protein model structure (PDB: 1T7G) [282], it is possible that the 
C6 regions between neighboring S proteins could self-interact along the viral entry process. 
Possible scenarios include that the self-interaction of the C6 regions may prepare the virus to 
attach onto the ACE2. Alternatively, the self-interaction of the C6 region happens post-
receptor-binding and leads to additional conformation changes within the S protein, which are 
essential for the subsequent steps of viral entry. Exogenous application of the C6 peptide 
could obstruct the self-interaction of this region and, hence, inhibit the viral receptor binding 
or affect the S protein conformational change following receptor binding. SARS-CoV 
primarily utilizes the ACE2 to enter the target cells, but it can also establish infection through 
interacting with DC/L-SIGN [28]. Most interestingly, the C6 region, specifically its N-
glycosylation site at N227, is also essential for the DC/L-SIGN-mediated viral entry and it is 
critical for the virus to achieve zoonotic transmission [28, 283, 284]. This raises the 
possibility that the C6 region may also participate in a glycan-mediated interaction with 
DC/L-SIGN and, thereby, facilitate the SARS-CoV entry into human cells. 
The receptor recognition by a Class I viral fusion glycoprotein prompts the structural changes 
within its transmembrane membrane-fusing unit, resulting in the exposure and insertion of 
the N-terminal FP into the target cell membrane, which extends the two HRs following the 
FP. At this pre-fusion stage, both of the HRs are believed to be in a trimeric state. Peptides 
derived from the MPER of the SARS-CoV S protein, the hydrophobic region following the 
trimeric C-terminal HR, was shown to be capable of oligomerizing (Paper II). Furthermore, 
substitutions of the three Trp residues within the S protein MPER-derived peptide with the 
aliphatic amino acid Ala abrogated the peptide oligomerization, while with the aromatic 
amino acid Phe restored the phenotype (Paper II). This raises the possibility that the MPER-
derived peptide or the S protein MPER could oligomerize through a zipper-like motif held 
together by multiple aromatic residues, i.e. an aromatic amino acid zipper (AAAZ) motif 
(Figure 27). The AAAZ motif is generated through the hydrophobic interaction (e.g. π-π 
interaction) between the interdigitating aromatic ring side-chains. Such hydrophobic 
interactions between aromatic amino acids including Trp, Phe and tyrosine (Tyr), have been 
reported to stabilize peptide or protein structures and to induce their oligomerization [285]. 
Due to the essentialness of the Trp residues in its oligomerization, the S protein MPER-
derived peptide likely oligomerized through a Trp zipper, where the indole ring side-chains of 
the Trp residues of the neighboring MPER-derived peptides were stacked at various angles 
[286-288]. Previously, a peptide derived from the HIV-1 Env MPER has also been reported 
to be able to oligomerize [169]. MPER is an envelope-proximal region and contains multiple 
membrane-active elements such as Trp and lipid-interacting motifs, which are instrumental 
for lipid mixing and the envelope-membrane fusion during the entry of SARS-CoV and HIV. 
It is puzzling how the MPER is folded into the viral fusion proteins so that it is not activated 
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prior to the actual membrane fusion, as such premature activation of the MPER would disrupt 
the virus envelope. The answer might lie in the ability of the MPER to trimerize, as a 
continuation to the trimeric stalk-like C-terminal HR. It is possible that the oligomerization of 
MPER, maintained by the Trp residues, serves as a safety mechanism to preclude the 
membrane-active sequence elements from interacting with the envelope prematurely.   
 
 
Figure 27. Schematic representation of the Class I viral fusion protein-mediated viral entry, at 
the pre-fusion stage. At the pre-fusion stage, post-receptor binding and prior to 6-HB formation, we 
propose that the MPER on neighboring fusion proteins trimerize via an AAAZ motif formed between 
the aromatic residues within MPER. Grey cylinder, FP or IFP; blue cylinder, N-HR; green 
cone/cylinder, C-HR; magenta, MPER; purple, TMD; and grey line, cytoplasmic tail. The Trp 
residues within MPER are highlighted by the pentagons in purple. The viral envelope is in blue and 
the target cell membrane in orange.  
 
As the viral entry process proceeds, the extended HRs will slowly come together to form the 
6-HB fusion core, where the C-terminal HR trimers dissociate and each monomer binds anti-
parallel onto the trimeric N-terminal HR coiled-coil. The formation of the 6-HB fusion core is 
believed to be the key conformational change in bringing the viral envelop and cell 
membrane close for lipid mixing and fusion. Concurrently, the formation of 6-HB also 
approximates the FP and MPER, the highly hydrophobic regions upstream to the N-terminal 
HR and downstream to the C-terminal HR, respectively. The high hydrophobicity of both the 
MPER and FP indicates that there may be an interaction between these two regions. In this 
study, we could show that peptides derived from the SARS-CoV S protein MPER interacted 
selectively with a peptide derived from the IFP, which is the region immediately N-terminal 
to HR1. The SARS-CoV S protein contains two hydrophobic regions upstream to the N-
terminal HR, the FP and downstream thereof IFP [41, 42]. Previously, the potential 
interactions between the MPER, FP and IFP of the S protein have been investigated in 
artificial lipid membranes and/or vesicles [161], but these studies have generated inconsistent 
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data. An MPER-derived peptide could cooperatively disrupt lipid membranes with an IFP-
derived peptide but not an FP-derived peptide. Meanwhile, accessibility experiments suggest 
that an MPER-derived peptide interacted with an FP-derived peptide, but not one derived 
from the IFP [161]. In Paper II, the selective MPER-IFP interaction was confirmed both by 
biochemical crosslinking and by immunofluorescence staining on cellular membranes. The 
CD spectrum of an equimolar mixture of the MPER- and IFP-derived peptides shifted 4 nm 
to the left from the theoretical CD profile averaged from the individual profiles of either 
peptide, further suggesting that there is a weak MPER-IFP interaction existing in solution. 
The preference of the MPER to interact with the IFP but not with the FP may be owing to the 
closer physical proximity between the MPER and IFP upon the formation of the fusion core 
in the S protein, when the FP is directed to insert into the target membrane. Previously, a 
similar interaction has been reported between the HIV-1 Env MPER and FP. In a mechanistic 
study, it was shown that inclusion of the MPER and FP sequences to synthetic peptides 
derived from the N- and C-terminal HRs, respectively, enhanced the stability of the 6-HB, 
which may provide additional free energy to approximate the opposing membranes [152, 
169, 170] (Figure 28).  
 
 
Figure 28. Schematic representation of the formation of 6-HB fusion core, in conjunction with 
the MPER-FP interaction. Upon the formation of 6-HB, we propose that the MPER will interact 
with the FP, or the immediate hydrophobic region upstream of the N-HR. The MPER-FP interaction 
strengthens the 6-HB and facilitates the approximation of the opposing membranes. The increase in 
local lipidity could induce the entire or part(s) of the MPER to adopt helical conformation, which 
exposes its membrane-active sequence elements, such as Trp, for lipid mixing. The color scheme in 
this figure follows that in Figure 27. 
 
As the opposing membrane approaches one-another, the local lipidity increases. In both a 
previous study and as observed in Papers II and III, an increase in the environmental 
hydrophobicity or lipidity could induce an increase of helical contents within the peptides 
derived from the MPER of both HIV-1 Env and SARS-CoV S proteins [172, 173]. This 
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lipidity-induced structural transformation may facilitate the exposure of the membrane-active 
sequence elements within the MPER, which thereafter participate in lipid mixing (Figure 28). 
Indeed, in association with lipid membrane, a peptide derived from the HIV-1 Env MPER 
exhibited a bended two-helix conformation, where the tilted N-terminal α-helix lies on the 
membrane, while the flat C-terminal helical segment is embedded in the membrane putatively 
for lipid mixing. Furthermore, both the structural transformation of the MPER-derived 
peptide, and its interactions with the N-terminal hydrophobic region and the lipid membranes 
required essential participation of the Trp residues (Papers II and III) [166]. This is in 
agreement with the previous observations that the TrpAla substitutions in the MPER 
abrogated the entry/infectivity of SARS-CoV and HIV-1 [158, 162, 163]. We propose that 
the interaction between the MPER and the immediate hydrophobic region upstream to the N-
HR, together with the lipidity-induced MPER structural transformation, may collectively 
serve as a general, Trp-dependent mechanism among the Class I viral fusion glycoproteins in 
promoting the membrane fusion (Figure 28). 
While we have studied the effects of Class I viral fusion glycoproteins on the viral entry 
process, we could also identify regions that affected viral infectivity during the post-entry 
steps of viral replication. Previous studies have suggested that the HIV-1 Env expression 
down-regulates the steady-state intracellular levels of p55/Gag protein, at both protein level 
through the Env cytoplasmic tails and at the RNA level through acting on the Rev response 
elements within env [289, 290]. In Papers III and IV, we observed two more Env regions 
that regulated the expression of p55/Gag, the MPER and the ss. Ala substitutions of the Trp 
residues within the Env MPER moderately decreased the Env expression, while significantly 
elevating the intracellular p55/Gag levels (Paper III). Contradictory to the previous studies 
on the relationship between Env and p55/Gag expressions, the extent of the increase in 
p55/Gag levels did not correlate with the decrease in Env expression. This suggests that the 
Env MPER could regulate p55/Gag expression in a yet-to-be defined mechanism.  
Besides the MPER, the ss of Env was shown to down-regulate the p55/Gag level and to 
suppress viral production, unrelated to the Env expression level. In Paper IV, N-terminal 
truncation of the Env ss elevated the expression levels of viral proteins, p55/Gag, p160/Gag-
pol and Vif. The positively charged n region (MRVKEKYQHLWRWGWK, aa 1-16) within 
the Env ss functions to retard the protein folding and maturation in the ER [122, 123]. 
However, according to our observation and the studies carried out by other groups, the basic 
residues of this region appear to be entirely dispensable for the Env expression or maturation 
[122, 291]. The N-terminal 8 aa are completely dispensable for adequate Env expression, and 
truncation of the first 19 aa does not affect the ER-targeting and maturation of the mutant Env 
protein [252]. These observations exclude the possibility that the elevation of viral production 
upon N-terminal truncation of the Env ss was due to an altered Env production. Instead, by 
studying the expression of an LTR-driven reporter molecule in the presence of either N-
terminally truncated or WT ss, we could show that the WT Env ss suppressed the viral 
replication through the inhibition of the LTR-dependent viral genome transcription.  
  51 
As compared to the ss within the ER-residing Env, which is likely constrained 
temporospatially, the signal peptide that is cleaved off the ss has bigger freedom to conduct 
the necessary interactions for suppressing the viral replication. The potential involvement of 
the Env signal peptide is supported by the observation that the Env signal peptide is not 
degraded immediately, but processed and further released into the cytosol [292]. A processed 
signal peptide fragment containing the N-terminal 23 aa may further antagonize the cell 
signaling molecule calmodulin (CaM) [292]. CaM is a calcium-sensor protein that can 
promiscuously interact with hundreds of proteins and thereby regulates numerous cellular 
functions and metabolic pathways [293-299]. In relation to HIV-1, a CaM-binding site has 
been identified in vitro within Tat [300]. The Tat CaM-binding sequence 
(QVCFITKALGISYGRKKRRQR) further overlaps substantially with the Tat viral RNA-
binding motif RKKRRQRRR (a.a.49 – 57 in strain NL4-3) [300-302]. This raises the 
possibility that the Tat-LTR interaction and/or proviral transcription could be influenced by 
the Tat-CaM interaction, which in turn could be linked to the signal peptide-CaM interaction. 
Alternatively, the Env signal peptide or its fragments could translocate into the nucleus and 
directly influence the LTR-driven proviral transcription. Signal peptides derived from the 
Env of some other retroviruses have been shown to accumulate in the nucleus or at the viral 
budding sites to exert various post-ER-targeting activities, [303-309]. However, prediction 
using online software failed to identify a nuclear localization signal (NLS) within the HIV-1 
Env ss. The lack of ss-specific antibody, owing to unsuccessful attempts to immunize rabbits 
with peptides derived from the Env ss, further hampered our ability to localize the Env signal 
peptide in HIV-1 infected cells.  
The putative Env signal peptide-induced suppression of the HIV-1 production demonstrated a 
time- and dose-dependency. This indicates that the suppression was at a late stage of the viral 
replication cycle when sufficient level of Env and, hence, signal peptide would have 
accumulated. This could be part of a negative feedback mechanism, which would favor 
sustainability over sporadic viral production and protect the host cells from fast exhaustion. 
Besides regulating the viral entry and/or viral replication, all three interaction-mediating 
sequences studied here, the C6 region within SARS-CoV S protein, the MPERs within S 
protein and HIV-1 Env, and the Env ss; are located to surface exposed accessible regions 
with high levels of sequence conservation. These characteristics make them promising targets 
for therapeutic interventions and for diagnostic recognition of the virus. In Papers I, II and 
III, peptidyl analogues of the C6 region and MPER were studied for their use as diagnostic 
tool and as fusion inhibitors, respectively. We could show that peptide C6 at 2 μM detected 
the S protein expression in an immunofluorescence assay, with comparable staining pattern 
and signal as a conventional anti-S protein antibody (Paper I). This ability of peptide C6 to 
mimic an antibody in detecting protein expression opens up its potential to be further 
developed as a peptide-based diagnostic and research tool. In Papers II and III, the synthetic 
MPER-derived peptides showed dose-dependent inhibition of the entry and infection of 
coronavirus and HIV-1, putatively through dominant negative binding to the fusion 
glycoproteins, thereby, obstructing the MPER to oligomerize or heteromerize with the FP. 
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Additionally, the membrane-active sequence elements, i.e. the aromatic residues and 
cholesterol-interacting CRAC motif, could anchor the MPER-derived peptides to lipid rafts, 
the viral entry sites of both SARS-CoV and HIV-1(Paper II) [187, 201, 202, 275-277]. 
Elimination of either Trp residues or the CRAC motif within the MPER-derived peptides 
abrogated the anti-viral efficacy of the peptides (Paper III). This suggests that the local 
enrichment of the MPER-derived peptides to the viral entry sites may additionally contribute 
to their anti-viral efficacy [187, 201, 202, 275-277].  
Peptide multimerization, which increases the interaction sites on peptides, is an effective way 
to enhance the avidities of peptide-ligand interactions. It was employed in this study to 
enhance the protein detection sensitivity of peptide C6 (Paper I) and the viral inhibition 
efficacies of the Env MPER-derived peptides (Paper III). Albeit effective in enhancing the 
C6-S protein interaction, C6 dimerization also increased the propensity of the C6 sequence to 
self-aggregate and form amyloid-like fibrils (Paper I). This prevented the dimeric C6 peptide 
to be applied to detect the S protein expression in vitro. This could be potentially 
circumvented by including a β-sheet-breaker residue such as Pro into the peptide sequence. 
This method has been shown to effectively reduce the aggregation propensity of self-
interacting peptides, without sacrificing their ability to specifically bind to their respective 
target protein [234, 310, 311]. Furthermore, multimerization of a peptide to enhance its 
interaction with the cognate protein, such as the interaction between the MPER-derived 
peptides and HIV-1 Env, should be applied with structural consideration. In Paper III, 
peptide dimerization up to 5-fold enhanced the antiviral efficacies of HIV-1 Env-derived 
peptides containing the entire MPER and a very short HR2 sequence. Notably, the N-
terminal, as compared to C-terminal, dimerization of the MPER-derived peptides was more 
effective in enhancing the viral inhibition of the peptides. The better anti-viral efficacies of 
the N-terminal dimers are in agreement with their resemblance of the active ‘tripod’ 
conformation of Env MPER, where the MPER N-termini trimerize and the C-termini stay 
separated and membrane-bound [145, 312]. In contrast, C-terminal dimerization disfavors the 
MPER-derived peptides to mimic the active conformation of the Env MPER. Moreover, C-
terminal dimerization could further constrain the peptide C-termini and prevent the CRAC 
motif from interacting with membranes and anchoring the peptides to the viral entry sites. 
This study focused on three interaction-mediating sequences within two Class I viral fusion 
glycoproteins. They are the C6 sequence upstream of the RBD within the SARS-CoV S 
protein, the MPER within both the S protein and HIV-1 Env, and the ss of Env. We could 
show that they regulate the viral infectivity at different stages of the viral replication, and 
surprisingly not just confined to the viral entry process. Their potentials in diagnostic and 
therapeutic applications have also being studied and confirmed with their peptide analogues. 
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6 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES  
The main findings of this thesis are: 
 The identifiaction of a self-interacting sequence GINITNFR upstream of the RBD 
within the SARS-CoV S protein, which could potentially form cross-β spine steric 
zipper and which further could be applied to detect the S protein expression in vitro. 
 
 The identification of the Trp-dependent oligomerization of a SARS-CoV S protein 
MPER-derived peptide and its selective heteromerization with an IFP-derived 
peptide.  
 
 The peptides derived from the SARS-CoV S protein or HIV-1 Env MPER could 
inhibit viral entry in a dose-dependent manner, where the membrane-active sequential 
elements within the MPER-derived peptides, the Trp residues and/or the cholesterol-
interacting motifs, played essential roles.  
 
 The peptide-protein interaction avidity and the anti-viral efficacy could be effetively 
enhanced through peptide multimerization.  
 
 HIV-1 Env has profound regulatory roles on viral replication and on viral protein 
expression, as observed in the mutant viruses containing Env with an Ala-substituted 
MPER or a N-terminally truncated signal sequence. Particularly, the HIV-1 Env 
signal sequence could downregulate the viral production in a time-, dose- and LTR-
dependent manner. 
Rapid and economic generation of practical detection reagent is instrumental for the 
diagnosis and treatment of viral infections, particularly for emerging pathogens. Antibodies 
have been invaluable research, diagnostic and therapeutic tools, due to their potent and 
specific interaction with the antigenic epitopes. However, the requirement of an 
immunogenic molecule and the stringent storage and production conditions limit the field 
applications of antibodies. These issues could be partially circumvented by identifying self-
binding peptides from the protein-of-interest, such as GINITNFR within the SARS-CoV S 
protein. The sequence-specific peptide-protein interactions could potentially enable these 
self-binding peptides to mimic functions of antibodies and to be further developed as 
alternatives to antibodies. Nevertheless, future studies are needed to develop effective 
strategies to improve the interaction avidity and specificity between the self-binding peptides 
and the protein-of-interest. According to previous research and the work reported on in this 
thesis, MPER within the Class I viral fusion glycoproteins facilitate the membrane fusion 
with its flexible structure, dynamic oligomerization states, and multiple interaction partners 
including both protein domains and lipid molecules. All of these interactions require essential 
participation of the conserved Trp residues. To integrate and relate the observed findings to 
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viral entry and inhibition in a temporal fashion, detailed structural study under biologically 
relevant environments and in the context of the whole protein are needed. Finally, the 
mechanism through which the HIV-1 Env signal sequence suppressed the viral production 
requires detailed studies, for this interesting effect to be exploited therapeutically.  
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